HCP, INC. Form 10-Q May 02, 2013
Table of Contents

UNITED STA SECURITIES AND EXCHAI	
Washington, D.C. 20	0549
FORM 10-	-Q
(Mark One) x QUARTERLY REPORT PURSUANT TO SECTION EXCHANGE ACT OF 1934.	13 OR 15(d) OF THE SECURITIES
For the quarterly period ended	March 31, 2013.
OR	
o TRANSITION REPORT PURSUANT TO SECTION EXCHANGE ACT OF 1934	N 13 OR 15(d) OF THE SECURITIES
For the transition period from	to

Commission file number 001-08895

1

Edgar Filing: HCP, INC Form 10-Q

HCP, INC.

(Exact name of registrant as specified in its charter)

Maryland

33-0091377 (I.R.S. Employer Identification No.)

(State or other jurisdiction of incorporation or organization)

> 3760 Kilroy Airport Way, Suite 300 Long Beach, CA 90806 (Address of principal executive offices)

(562) 733-5100 (Registrant s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES x NO o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit and post such files). YES x NO o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer x

Accelerated Filer o

Non-accelerated Filer o (Do not check if a smaller reporting company) Smaller Reporting Company o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) YES o NO x

As of April 25, 2013, there were 454,486,181 shares of the registrant s \$1.00 par value common stock outstanding.

Table of Contents

HCP, INC.

INDEX

PART I. FINANCIAL INFORMATION

Item 1.	Financial Statements:	
	Condensed Consolidated Balance Sheets	3
	Condensed Consolidated Statements of Income	4
	Condensed Consolidated Statements of Comprehensive Income	5
	Condensed Consolidated Statements of Equity	6
	Condensed Consolidated Statements of Cash Flows	7
	Notes to the Condensed Consolidated Financial Statements	8
Item 2.	Management s Discussion and Analysis of Financial Condition and Results of Operations	23
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	34
Item 4.	Controls and Procedures	35
	PART II. OTHER INFORMATION	
Item 1A.	Risk Factors	36
Item 2.	<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	36
Item 6.	<u>Exhibits</u>	36
<u>Signatures</u>		38
	2	

HCP, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share data)

(Unaudited)

		March 31, 2013	December 31, 2012
ASSETS			
Real estate:			
Buildings and improvements	\$	10,623,382	\$ 10,537,484
Development costs and construction in progress		223,534	236,864
Land		1,853,392	1,850,397
Accumulated depreciation and amortization		(1,822,628)	(1,739,718)
Net real estate		10,877,680	10,885,027
Net investment in direct financing leases		6,921,421	6,881,393
Loans receivable, net		291,870	276,030
Investments in and advances to unconsolidated joint ventures		209,810	212,213
Accounts receivable, net of allowance of \$1,632 and \$1,668, respectively		32,183	34,150
Cash and cash equivalents		47,547	247,673
Restricted cash		37,675	37,848
Intangible assets, net		537,692	552,701
Other assets, net		776,853	788,520
Total assets(1)	\$	19,732,731	\$ 19,915,555
LIABILITIES AND EQUITY			
Bank line of credit	\$,	\$
Term loan		208,213	222,694
Senior unsecured notes		6,563,749	6,712,624
Mortgage debt		1,680,792	1,676,544
Other debt		78,836	81,958
Intangible liabilities, net		101,633	105,909
Accounts payable and accrued liabilities		238,583	293,994
Deferred revenue		64,866	68,055
Total liabilities(2)		8,950,672	9,161,778
Commitments and contingencies			
Common stock, \$1.00 par value: 750,000,000 shares authorized; 454,416,748 and			170 101
453,191,321 shares issued and outstanding, respectively		454,417	453,191
Additional paid-in capital		11,218,702	11,180,066
Cumulative dividends in excess of earnings		(1,075,249)	(1,067,367)
Accumulated other comprehensive loss		(16,604)	(14,653)
Total stockholders equity		10,581,266	10,551,237
T *		15 105	14.750
Joint venture partners		15,185	14,752
Non-managing member unitholders		185,608	187,788
Total conity		200,793	202,540
Total equity	ď	10,782,059	10,753,777
Total liabilities and equity	\$	19,732,731	\$ 19,915,555

(1)	The Company s consolidated total assets at March 31, 2013 and December 31, 2012, include assets of certain variable interest entities (VIEs) that can only
be us	ed to settle the liabilities of those VIEs as follows: accounts receivable, net, \$2 million in each period presented; cash and cash equivalents, \$10 million in
each	period presented; and other assets, net, \$3 million and \$2 million, respectively. See Note 16 to the Condensed Consolidated Financial Statements for
additi	ional information.

(2) The Company's consolidated total liabilities at March 31, 2013 and December 31, 2012, include liabilities of certain VIEs for which the VIE creditors do not have recourse to HCP, Inc. as follows: other debt, \$0.2 million in each period presented; accounts payable and accrued liabilities, \$15 million and \$14 million, respectively; and deferred revenue, \$2 million in each period presented. See Note 16 to the Condensed Consolidated Financial Statements for additional information.

See accompanying Notes to the Condensed Consolidated Financial Statements.

HCP, INC.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(In thousands, except per share data)

(Unaudited)

		Three Months Ended March 31,		
		2013		2012
Revenues:				
Rental and related revenues	\$	285,476	\$	241,151
Tenant recoveries		24,203		22,650
Resident fees and services		36,891		36,179
Income from direct financing leases		156,870		154,535
Interest income		12,386		819
Investment management fee income		443		493
Total revenues		516,269		455,827
Costs and expenses:				
Interest expense		109,351		103,752
Depreciation and amortization		104,717		85,280
Operating		73,605		67,333
General and administrative		20,744		20,089
Total costs and expenses		308,417		276,454
•				
Other income, net		12,012		436
, and the second		,		
Income before income taxes and equity income from unconsolidated joint ventures		219,864		179,809
Income taxes		(881)		709
Equity income from unconsolidated joint ventures		14,801		13,675
Income from continuing operations		233,784		194,193
8 T				, , , ,
Discontinued operations:				
Loss before gain on sales of real estate				(485)
Gain on sales of real estate				2,856
Total discontinued operations				2,371
1 out discontinued operations				2,8 / 1
Net income		233,784		196,564
Noncontrolling interests share in earnings		(3,199)		(3,184)
Net income attributable to HCP, Inc.		230,585		193,380
Preferred stock dividends		250,505		(17,006)
Participating securities share in earnings		(478)		(1,117)
Net income applicable to common shares	\$	230,107	\$	175,257
Technical applicable to common shares	Ψ	230,107	Ψ	173,237
Basic earnings per common share:				
Continuing operations	\$	0.51	\$	0.42
Discontinued operations	φ	0.51	φ	0.42
Net income applicable to common shares	\$	0.51	\$	0.43
	Ф	0.51	Ф	0.43
Diluted earnings per common share:	¢	0.51	¢	0.42
Continuing operations	\$	0.51	\$	0.42
Discontinued operations	¢.	0.51	¢	0.01
Net income applicable to common shares	\$	0.51	\$	0.43

Weighted average shares used to calculate earnings per common share:

Basic	4	453,651	410,018
Diluted	4	454,613	411,661
Dividends declared per common share	\$	0.525	\$ 0.50

See accompanying Notes to the Condensed Consolidated Financial Statements.

HCP, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(In thousands)

(Unaudited)

	Three Months En 2013	nded Ma	rch 31, 2012
Net income	\$ 233,784	\$	196,564
Other comprehensive income (loss): Unrealized gains on securities:			
Unrealized gains	1,355		1,304
Reclassification adjustment realized in net income	(9,131)		
Change in net unrealized gains on cash flow hedges:			
Unrealized gains	5,320		276
Reclassification adjustment realized in net income	272		89
Change in Supplemental Executive Retirement Plan obligation	55		45
Foreign currency translation adjustment	178		202
Total other comprehensive income (loss)	(1,951)		1,916
Total comprehensive income	231,833		198,480
Total comprehensive income attributable to noncontrolling interests	(3,199)		(3,184)
Total comprehensive income attributable to HCP, Inc.	\$ 228,634	\$	195,296

See accompanying Notes to the Condensed Consolidated Financial Statements.

HCP, INC.

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY

(In thousands, except per share data)

(Unaudited)

			Additional	Dividends	Accumulated Other	Total	Total	
	Comm Shares	on Stock Amount	Paid-In Capital		omprehensive ncome (Loss)	Stockholders N Equity	Ioncontrolling Interests	Total Equity
January 1, 2013	453,191	\$ 453,191	•		. ,		\$ 202,540 \$	10,753,777
Net income				230,585		230,585	3,199	233,784
Other								
comprehensive loss					(1,951)	(1,951)		(1,951)
Issuance of common								
stock, net	555	555	13,901			14,456	(2,179)	12,277
Repurchase of								
common stock	(14)	(14)	(675)			(689)		(689)
Exercise of stock								
options	685	685	19,980			20,665		20,665
Amortization of								
deferred								
compensation			5,430			5,430		5,430
Common dividends				(220, 467)		(220, 467)		(220, 467)
(\$0.525 per share)				(238,467)		(238,467)		(238,467)
Distributions to								
noncontrolling interests							(2.754)	(2.754)
Issuance of							(3,754)	(3,754)
noncontrolling								
interests							987	987
March 31, 2013	454,417	\$ 454,417	\$ 11,218,702	\$ (1,075,249) \$	\$ (16,604)	\$ 10,581,266		10,782,059

						Cumulative Ac	cumulated			
					Additional	Dividends	Other	Total	Total	
	Prefer	ed Stock	Comm	on Stock	Paid-In	In Excess Cor	nprehensiv&	tockholders <mark>/</mark>	loncontrolling	Total
	Shares	Amount	Shares	Amount	Capital	Of Earnings Inc	come (Loss)	Equity	Interests	Equity
January 1, 2012	11,820	\$ 285,173	408,629	\$ 408,629	\$ 9,383,536	\$ (1,024,274)\$	(19,582)\$	9,033,482	\$ 187,140 \$	9,220,622
Net income						193,380		193,380	3,184	196,564
Other										
comprehensive										
income							1,916	1,916		1,916
Preferred stock										
redemption	(11,820)	(285,173)				(11,723)		(296,896)	J	(296,896)
Issuance of										
common stock, net			9,559	9,559	358,397			367,956	(1,034)	366,922
Repurchase of										
common stock			(167)	(167)	(6,817))		(6,984)	J	(6,984)
Exercise of stock										
options			1,412	1,412	36,219			37,631		37,631
					5,373			5,373		5,373

Edgar Filing: HCP, INC. - Form 10-Q

Amortization of							
deferred							
compensation							
Preferred							
dividends				(5,283)	(5,28	3)	(5,283)
Common							
dividends (\$0.50							
per share)				(205,784)	(205,78	4)	(205,784)
Distributions to							
noncontrolling							
interests						(3,912)	(3,912)
Issuance of							
noncontrolling							
interests						181	181
Purchase of							
noncontrolling							
interests						(388)	(388)
March 31, 2012	\$ 419,433	\$ 419,433	\$ 9,776,708	\$ (1,053,684)\$	(17,666) \$ 9,124,79	1 \$ 185,171	\$ 9,309,962

See accompanying Notes to the Condensed Consolidated Financial Statements.

HCP, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands) (Unaudited)

Rest income \$ 233,784 \$ 196,564 Actinsments to reconcile net income to net cash provided by operating activities: Use preciation and amortization of real estate, in-place lease and other intangibles: Discontinuing operations 104,717 \$85,280 Discontinuing operations 104,717 \$85,280 Discontinuing operations (78) (697) Amortization of deferred compensation 5,430 5,373 Amortization of deferred financing costs, net (18,793) (9,927) Amortization of deferred financing lease interest accretion (24,266) (25,878) Straight-line rents (18,793) (9,927) Loam and direct financing lease interest accretion (24,266) (25,878) Deferred rental revenues 1,257 1,839 Equity income from unconsolidated joint ventures (10,977) 1,339 Use to a contraint problem unconsolidated joint ventures (10,977) 2,300 Defivative (gains) losses, net (10,977) 2,300 Changes in: (10,977) 2,300 Changes in: (2,969) 2,330 Net cash provided by		Three Months Ended March 31, 2013 2012			
Net income \$ 233,784 \$ 196,564 Adjustments to reconcile net income to net cash provided by operating activities: Uniformal activities Uniformal activities Depreciation and amortization of real estate, in-place lease and other intangibles: 104,717 \$5,280 Continuing operations 778 (697) Amortization of above and below market lease intangibles, net 778 (697) Amortization of deferred compensation 5,433 5,373 Amortization of deferred compensation 4,644 4,529 Straight-line rents (18,793) 9,927 Loan and direct financing lease interest accretion (24,566) (25,878) Deferred rental revenues 11,257 1,839 Deferred rental revenues (10,270) 12,856 Gain on sales of real estate (10,977) 2,856 Marketable securities gains, net (10,977) 2,856 Derivative (gains) losses, net (10,977) 2,200 Cother assets (8,699) 7,877 Accounts receivable, net 1,967 2,300 Other assets (8,699) 7,28	Cash flows from operating activities:	2010	2412		
Depreciation and amortization of real estate, in-place lease and other intangibles: 85,280 Continuing operations 1,296 Discontinued operations (697) Amortization of above and below market lease intangibles, net (78) (537) Amortization of deferred compensation 5,430 5,373 Amortization of deferred financing costs, net 4,644 4,529 Loan and direct financing lease interest accretion (24,266) (25,878) Deferred rental revenues 1,257 1,839 Equity in income from unconsolidated joint ventures 803 913 Sistributions of earnings from unconsolidated joint ventures 803 913 Gain on sales of real estate (10,977) (2,856) Marketable securities gains, net (10,977) 2,300 Derivative (gains) losses, net (10,977) 2,300 Changes in: 1,967 2,300 Charges in: 1,967 2,300 Charges in: 1,967 2,300 Charges in: 1,967 2,300 Cherises (with (gains) losses, net 1,967 2,300 <td></td> <td>\$ 233,784</td> <td>\$ 196,564</td>		\$ 233,784	\$ 196,564		
Continuing operations 104,717 85,280 Discontinued operations 2,996 Amortization of above and below market lease intangibles, net (78) (697) Amortization of deferred compensation 5,430 5,373 Amortization of deferred financing costs, net 4,644 4,529 Straight-line rents (18,793) (9,227) Loan and direct financing lease interest accretion (24,266) (25,878) Deferred rental revenues 1,257 1,839 Equity income from unconsolidated joint ventures (14,801) (13,675) Distributions of carnings from unconsolidated joint ventures (10,977) (2,856) Marketable securities gains, net (10,977) (2,856) Derivative (gains) losses, net (10,97) 20 Characteristic gains, net	Adjustments to reconcile net income to net cash provided by operating activities:				
Discontinued operations 2,996 Amortization of above and below market lease intangibles, net 78 6997 Amortization of deferred compensation 5,430 5,373 Amortization of deferred financing costs, net 4,644 4,529 Straight-line rents (18,793) 9,927 Loan and direct financing lease interest accretion (24,266) (25,878) Deferred rental revenues 1,257 1,839 Equity income from unconsolidated joint ventures 803 913 Distributions of earnings from unconsolidated joint ventures 803 913 Gain on sales of real estate (10,977) 2,856 Marketable securities gains, net (10,977) 2.00 Changes in: (105) 23 Accounts receivable, net 1,967 2,300 Other assets (8,699) (7,877) Accounts payable and accrued liabilities (60,533) (52,619) Net cash provided by operating activities (21,350) (22,340) Cash flows from investing activities (25,554) (22,340) Leasing costs and tenan					
Amortization of above and below market lease intangibles, net (78) (597) Amortization of deferred compensation 5,430 5,373 Amortization of deferred financing costs, net 4,644 4,529 Straight-line rents (18,793) (9,927) Loan and direct financing lease interest accretion (24,266) (25,878) Deferred rental revenues 1,257 1,839 Equity income from unconsolidated joint ventures 803 913 Gain on sales of real estate 803 913 Marketable securities gains, net (10,977) 203 Derivative (gains) losses, net (105) 203 Charges in: (10,977) 2,300 Accounts receivable, net 1,967 2,300 Other assets (60,533) (52,619) Net cash provided by operating activities 214,350 186,468 Cash flows from investing activities (25,654) Development of real estate (25,554) Eequisitions of real estate (8,999) (8,931) Leasing costs and tenant and capital improvements 568		104,717	85,280		
Amortization of deferred compensation 5,430 5,373 Amortization of deferred financing costs, net 4,644 4,529 Straight-line rents (18,793) (9,927) Loan and direct financing lease interest accretion (24,266) (25,878) Deferred rental revenues 1,257 1,839 Equity income from unconsolidated joint ventures (14,801) (13,675) Distributions of earnings from unconsolidated joint ventures 803 913 Sain on sales of real estate (10,977) 200 Charlestable securities gains, net (10,977) 200 Changes in: 1,967 2,300 Changes in: 1,967 2,300 Changes in: (60,533) (52,619) Net cash provided by operating activities (8,699) (7,877) Accounts payable and accrued liabilities (60,533) (52,619) Net cash provided by operating activities (8,699) (7,877) Accounts payable and accrued liabilities accivates (8,699) (7,877) Net ash flows from investing activities (8,59) (8,931)	Discontinued operations		2,996		
Amortization of deferred financing costs, net (18,793) (9,927) Loan and direct financing lease interest accretion (24,266) (28,2878) Deferred rental revenues (1,257) 1,839 Equity income from unconsolidated joint ventures (1,257) 1,839 Equity income from unconsolidated joint ventures 803 913 Gain on sales of real estate (10,977) Marketables securities gains, net (10,977) Derivative (gains) losses, net (10,977) Accounts receivable, net 1,967 2,300 Other assets (8,699) (7,877) Accounts payable and accrued liabilities (8,699) (7,877) Accounts payable and accrued liabilities (8,699) (7,877) Accupisitions of real estate (25,654) 21,4350 186,468 Cast provided by operating activities (25,654) 22,340 Leasing costs and tenal and capital improvements (8,959) (8,931) Proceeds from sales of real estate (25,654) 22,148 Leasing costs and tenant and capital improvements (8,959) (8,931) <	Amortization of above and below market lease intangibles, net	(78)	(697		
Straight-line rents (18,793) (9,927) Loan and direct financing lease interest accretion (24,266) (25,878) Deferred rental revenues 1,257 1,839 Equity income from unconsolidated joint ventures 803 913 Gain on sales of real estate (2,856) Marketable securities gains, net (10,977) Derivative (gains) losses, net (105) 203 Accounts receivable, net 1,967 2,300 Other assets (8,699) (7,877) Accounts payable and accrued liabilities (8,599) (8,816) Bect cash provided by operating activities 21,436 (8,549) Act and flows from investing activities (8,599) (8,931) Proceads from investing a	Amortization of deferred compensation	5,430	5,373		
Loan and direct financing lease interest accretion (24,266) (25,878) Deferred rental revenues 1,257 1,839 Equity in come from unconsolidated joint ventures (14,801) 1,3675 Distributions of earnings from unconsolidated joint ventures 803 913 Gain on sales of real estate (10,977) Derivative (gains) losses, net (105) 203 Changes in: 1,967 2,300 Accounts receivable, net 1,967 2,300 Other assets (8,699) (7,877) Accounts payable and accrued liabilities (60,533) (52,619) Net cash provided by operating activities 214,350 186,468 Cast flows from investing activities (25,554) 24,240 Leasing costs and tenant and capital improvements (8,959) (8,931) Proceeds from sales of real estate (25,554) 24,160 Leasing costs and tenant and capital improvements 28,030 27,128 Drincipal repayments on loans receivable 2,188 4,015 Proceeds from the sale of marketable securities 28,030 21,188	Amortization of deferred financing costs, net	4,644	4,529		
Deferred rental revenues 1,257 1,839 Equity income from unconsolidated joint ventures (14,801) (13,675) Distributions of earnings from unconsolidated joint ventures 803 913 Gain on sales of real estate (10,977) Marketable securities gains, net (1015) 203 Changes in:	Straight-line rents	(18,793)	(9,927		
Equity income from unconsolidated joint ventures (14,801) (13,675) Distributions of earnings from unconsolidated joint ventures 803 913 Gain on sales of real estate (10,977) 100 Derivative (gains) passes, net (105) 203 Charge in: (10,977) 2,300 Accounts receivable, net 1,967 2,300 Other assets (8,699) (7,877) Accounts payable and accrued liabilities (60,533) (52,619) Net cash provided by operating activities (80,533) (52,619) Net cash provided by operating activities (80,533) (52,619) Net cash growided by operating activities (80,533) (52,619) Development of real estate (8,933) (80,419) Development of real estate (8,931)	Loan and direct financing lease interest accretion	(24,266)	(25,878		
Distributions of earnings from unconsolidated joint ventures 803 913 Gain on sales of real estate (2.856) Marketable securities gains, net (10.977) Derivative (gains) losses, net (105) 203 Changes in:	Deferred rental revenues	1,257	1,839		
Gain on sales of real estate (2,856) Marketable securities gains, net (10,977) Derivative (gains) losses, net (105) 203 Changes in: (1967) 2,300 Accounts receivable, net 1,967 2,300 Other assets (86,99) 7,877 Accounts payable and accrued liabilities (60,533) (52,619) Net cash provided by operating activities 214,350 186,468 Cash flows from investing activities 214,350 186,468 Cash flows from investing activities (25,654) 2 Development of real estate (25,654) 2 Development of real estate, net (8,959) (8,931) Proceeds from sales of real estate, net (8,959) (8,931) Proceeds from the sale of marketable securities 28,030 2,716 Proceeds from the sale of marketable securities 28,030 2,716 Principal repayments on loans receivable (14,957) (9,939 Investments in loans receivable (14,957) (9,939) Increase) decrease in restricted cash 173	Equity income from unconsolidated joint ventures	(14,801)	(13,675		
Marketable securities gains, net (10,977) Derivative (gains) losses, net (105) 203 Changes in:	Distributions of earnings from unconsolidated joint ventures	803	913		
Derivative (gains) losses, net (105) 203 Changes in: 3 Accounts receivable, net 1,967 2,300 Other assets (8,699) (7,877) Accounts payable and accrued liabilities (60,533) (52,619) Net cash provided by operating activities 214,350 186,468 Cash flows from investing activities: 2 4,350 186,468 Cash flows from investing activities: 2 4,2350 186,468 2,340 2,2400 2,2340 2,2400 2,2340	Gain on sales of real estate		(2,856		
Changes in: 2,300 Accounts receivable, net 1,967 2,300 Other assets (8,699) (7,877) Accounts payable and accrued liabilities (60,533) (52,619) Net cash provided by operating activities 214,350 186,468 Cash flows from investing activities 321,4350 186,468 Cash flows from investing activities 225,554 186,468 Development of real estate (25,654) 22,340 Leasing costs and tenant and capital improvements (8,959) (8,931) Proceeds from sales of real estate, net 7,238 2,716 Proceeds from sales of real estate, net 28,030 2,716 Proceeds from the sale of marketable securities 28,030 2,716 Proceeds from the sale of marketable securities 28,030 2,716 Proceeds from the sale of marketable securities 1,133 (3,905) Investments in loans receivable 1,4957 (9,939) Investments in loans receivable 1,4957 (9,939) Increase) decrease in restricted cash 173 (3,905)	Marketable securities gains, net	(10,977)			
Accounts receivable, net 1,967 2,300 Other assets (8,699) (7,877) Accounts payable and accrued liabilities (60,533) (52,619) Net cash provided by operating activities 214,350 186,468 Cash flows from investing activities: Cash flows from investing activities Cash flows from investing activities Cash flows from activate asset for earl estate, net Distributions in excess of earnings from unconsolidated joint ventures 568 2,716 Proceeds from the sale of marketable securities 28,030	Derivative (gains) losses, net	(105)	203		
Other assets (8,699) (7,877) Accounts payable and accrued liabilities (60,533) (52,619) Net cash provided by operating activities 214,350 186,468 Cash flows from investing activities:	Changes in:				
Accounts payable and accrued liabilities (60,533) (52,619) Net cash provided by operating activities 214,350 186,468 Cash flows from investing activities:	Accounts receivable, net	1,967	2,300		
Net cash provided by operating activities 214,350 186,468 Cash flows from investing activities: 38,468 Acquisitions of real estate (25,654) Development of real estate (38,749) (22,340) Leasing costs and tenant and capital improvements (8,959) (8,931) Proceeds from sales of real estate, net 7,238 Distributions in excess of earnings from unconsolidated joint ventures 568 2,716 Proceeds from the sale of marketable securities 28,030 Principal repayments on loans receivable 4,015 Investments in loans receivable (14,957) (9,939) (Increase) decrease in restricted cash 173 (3,905) Net cash used in investing activities (57,360) (31,146) Cash flows from financing activities (57,360) (31,146) Cash Insurance of senior unsecured notes 450,000 Repayments of minancing activities (150,000) Repayments of mortgage debt (12,135) (10,057) Deferred financing costs (10,117) Net proceeds from the issuance of common stock and exercise of options 32,253 397,569 <td>Other assets</td> <td>(8,699)</td> <td>(7,877</td>	Other assets	(8,699)	(7,877		
Cash flows from investing activities: Acquisitions of real estate (25,654) Development of real estate (38,749) (22,340) Leasing costs and tenant and capital improvements (8,959) (8,931) Proceeds from sales of real estate, net 7,238 Distributions in excess of earnings from unconsolidated joint ventures 568 2,716 Proceeds from the sale of marketable securities 28,030 *** Principal repayments on loans receivable 2,188 4,015 Investments in loans receivable (14,957) (9,939) (Increase) decrease in restricted cash 173 (3,905) Net cash used in investing activities (57,360) (31,146) Cash flows from financing activities (57,360) (31,146) Cash flows from financing activities (57,360) (454,000) Issuance of senior unsecured notes (150,000) ** Repayment of senior unsecured notes (150,000) ** Repayments of mortgage debt (12,135) (10,057) Deferred financing costs (10,117) **	Accounts payable and accrued liabilities	(60,533)	(52,619		
Acquisitions of real estate (25,654) Development of real estate (38,749) (22,340) Leasing costs and tenant and capital improvements (8,959) (8,931) Proceeds from sales of real estate, net 7,238 Distributions in excess of earnings from unconsolidated joint ventures 568 2,716 Proceeds from the sale of marketable securities 28,030 *** Principal repayments on loans receivable (14,957) (9,939) Investments in loans receivable (14,957) (9,939) Investments in in loans receivable 173 (3,905) Net cash used in investing activities (57,360) (31,146) Net cash used in investing activities (57,360) (31,146) Cash flows from financing activities (57,360) (31,146) Ret borrowings (repayments) under bank line of credit 14,000 (454,000) Issuance of senior unsecured notes (150,000) Repayment of senior unsecured notes (150,000) Repayments of mortgage debt (12,135) (10,057) Deferred financing costs (10,057) Net proceeds from the	Net cash provided by operating activities	214,350	186,468		
Development of real estate (38,749) (22,340) Leasing costs and tenant and capital improvements (8,959) (8,931) Proceeds from sales of real estate, net 7,238 Distributions in excess of earnings from unconsolidated joint ventures 568 2,716 Proceeds from the sale of marketable securities 28,030 2 Principal repayments on loans receivable 2,188 4,015 Investments in loans receivable (14,957) (9,939) (Increase) decrease in restricted cash 173 (3,905) Net cash used in investing activities (57,360) (31,146) Cash flows from financing activities (57,360) (31,146) Use borrowings (repayments) under bank line of credit 14,000 (454,000) Issuance of senior unsecured notes (150,000) (150,000) Repayment of senior unsecured notes (150,000) (10,057) Deferred financing costs (10,117) (10,117) Net proceeds from the issuance of common stock and exercise of options 32,253 397,569 Dividends paid on common and preferred stock (238,467) (211,067) <tr< td=""><td>Cash flows from investing activities:</td><td></td><td></td></tr<>	Cash flows from investing activities:				
Leasing costs and tenant and capital improvements (8,959) (8,931) Proceeds from sales of real estate, net 7,238 Distributions in excess of earnings from unconsolidated joint ventures 568 2,716 Proceeds from the sale of marketable securities 28,030	Acquisitions of real estate	(25,654)			
Proceeds from sales of real estate, net 7,238 Distributions in excess of earnings from unconsolidated joint ventures 568 2,716 Proceeds from the sale of marketable securities 28,030 28,030 Principal repayments on loans receivable 2,188 4,015 Investments in loans receivable (14,957) (9,939) (Increase) decrease in restricted cash 173 (3,905) Net cash used in investing activities (57,360) (31,146) Cash flows from financing activities: *** *** Net borrowings (repayments) under bank line of credit 14,000 (454,000) Issuance of senior unsecured notes (150,000) *** Repayment of senior unsecured notes (150,000) *** Repayments of mortgage debt (12,135) (10,057) Deferred financing costs (10,117) Net proceeds from the issuance of common stock and exercise of options 32,253 397,569 Dividends paid on common and preferred stock (238,467) (211,067) Issuance of noncontrolling interests 987 181 Distributions to noncontrolling interests	Development of real estate	(38,749)	(22,340		
Distributions in excess of earnings from unconsolidated joint ventures 568 2,716 Proceeds from the sale of marketable securities 28,030 Principal repayments on loans receivable 2,188 4,015 Investments in loans receivable (14,957) (9,939) (Increase) decrease in restricted cash 173 (3,905) Net cash used in investing activities (57,360) (31,146) Cash flows from financing activities: Net borrowings (repayments) under bank line of credit 14,000 (454,000) Issuance of senior unsecured notes (150,000) (12,135) (10,057) Repayments of mortgage debt (12,135) (10,117) Net proceeds from the issuance of common stock and exercise of options 32,253 397,569 Dividends paid on common and preferred stock (238,467) (211,067) Issuance of noncontrolling interests 987 181 Distributions to noncontrolling interests (3,754) (3,912) Net cash provided by (used in) financing activities (357,116) 158,597	Leasing costs and tenant and capital improvements	(8,959)	(8,931		
Proceeds from the sale of marketable securities 28,030 Principal repayments on loans receivable 2,188 4,015 Investments in loans receivable (14,957) (9,939) (Increase) decrease in restricted cash 173 (3,905) Net cash used in investing activities (57,360) (31,146) Cash flows from financing activities: Net borrowings (repayments) under bank line of credit 14,000 (454,000) Issuance of senior unsecured notes (150,000) Repayment of senior unsecured notes (150,000) Repayments of mortgage debt (12,135) (10,057) Deferred financing costs (10,117) Net proceeds from the issuance of common stock and exercise of options 32,253 397,569 Dividends paid on common and preferred stock (238,467) (211,067) Issuance of noncontrolling interests 987 181 Distributions to noncontrolling interests (3,754) (3,912) Net cash provided by (used in) financing activities (357,116) 158,597			7,238		
Principal repayments on loans receivable 2,188 4,015 Investments in loans receivable (14,957) (9,939) (Increase) decrease in restricted cash 173 (3,905) Net cash used in investing activities (57,360) (31,146) Cash flows from financing activities: *** *** Net borrowings (repayments) under bank line of credit 14,000 (454,000) Issuance of senior unsecured notes (150,000) *** Repayment of senior unsecured notes (12,135) (10,057) Deferred financing costs (10,117) *** Net proceeds from the issuance of common stock and exercise of options 32,253 397,569 Dividends paid on common and preferred stock (238,467) (211,067) Issuance of noncontrolling interests 987 181 Distributions to noncontrolling interests (3,754) (3,912) Net cash provided by (used in) financing activities (357,116) 158,597	Distributions in excess of earnings from unconsolidated joint ventures	568	2,716		
Investments in loans receivable (14,957) (9,939) (Increase) decrease in restricted cash 173 (3,905) Net cash used in investing activities (57,360) (31,146) Cash flows from financing activities: Net borrowings (repayments) under bank line of credit 14,000 (454,000) Issuance of senior unsecured notes (150,000) (10,057) Repayments of mortgage debt (12,135) (10,057) Deferred financing costs (10,117) Net proceeds from the issuance of common stock and exercise of options 32,253 397,569 Dividends paid on common and preferred stock (238,467) (211,067) Issuance of noncontrolling interests 987 181 Distributions to noncontrolling interests (3,754) (3,912) Net cash provided by (used in) financing activities (357,116) 158,597	Proceeds from the sale of marketable securities	28,030			
(Increase) decrease in restricted cash 173 (3,905) Net cash used in investing activities (57,360) (31,146) Cash flows from financing activities: *** Net borrowings (repayments) under bank line of credit 14,000 (454,000) Issuance of senior unsecured notes (150,000) ** Repayment of senior unsecured notes (12,135) (10,057) Deferred financing costs (10,117) Net proceeds from the issuance of common stock and exercise of options 32,253 397,569 Dividends paid on common and preferred stock (238,467) (211,067) Issuance of noncontrolling interests 987 181 Distributions to noncontrolling interests (3,754) (3,912) Net cash provided by (used in) financing activities (357,116) 158,597		2,188	4,015		
Net cash used in investing activities(57,360)(31,146)Cash flows from financing activities:(454,000)Net borrowings (repayments) under bank line of credit14,000(454,000)Issuance of senior unsecured notes450,000Repayment of senior unsecured notes(150,000)Repayments of mortgage debt(12,135)(10,057)Deferred financing costs(10,117)Net proceeds from the issuance of common stock and exercise of options32,253397,569Dividends paid on common and preferred stock(238,467)(211,067)Issuance of noncontrolling interests987181Distributions to noncontrolling interests(3,754)(3,912)Net cash provided by (used in) financing activities(357,116)158,597	Investments in loans receivable	(14,957)			
Cash flows from financing activities:Net borrowings (repayments) under bank line of credit14,000(454,000)Issuance of senior unsecured notes450,000Repayment of senior unsecured notes(150,000)Repayments of mortgage debt(12,135)(10,057)Deferred financing costs(10,117)Net proceeds from the issuance of common stock and exercise of options32,253397,569Dividends paid on common and preferred stock(238,467)(211,067)Issuance of noncontrolling interests987181Distributions to noncontrolling interests(3,754)(3,912)Net cash provided by (used in) financing activities(357,116)158,597	(Increase) decrease in restricted cash	173	(3,905		
Net borrowings (repayments) under bank line of credit14,000(454,000)Issuance of senior unsecured notes450,000Repayment of senior unsecured notes(150,000)Repayments of mortgage debt(12,135)(10,057)Deferred financing costs(10,117)Net proceeds from the issuance of common stock and exercise of options32,253397,569Dividends paid on common and preferred stock(238,467)(211,067)Issuance of noncontrolling interests987181Distributions to noncontrolling interests(3,754)(3,912)Net cash provided by (used in) financing activities(357,116)158,597		(57,360)	(31,146		
Issuance of senior unsecured notes450,000Repayment of senior unsecured notes(150,000)Repayments of mortgage debt(12,135)(10,057)Deferred financing costs(10,117)Net proceeds from the issuance of common stock and exercise of options32,253397,569Dividends paid on common and preferred stock(238,467)(211,067)Issuance of noncontrolling interests987181Distributions to noncontrolling interests(3,754)(3,912)Net cash provided by (used in) financing activities(357,116)158,597	Cash flows from financing activities:				
Repayment of senior unsecured notes(150,000)Repayments of mortgage debt(12,135)(10,057)Deferred financing costs(10,117)Net proceeds from the issuance of common stock and exercise of options32,253397,569Dividends paid on common and preferred stock(238,467)(211,067)Issuance of noncontrolling interests987181Distributions to noncontrolling interests(3,754)(3,912)Net cash provided by (used in) financing activities(357,116)158,597	Net borrowings (repayments) under bank line of credit	14,000	(454,000		
Repayments of mortgage debt(12,135)(10,057)Deferred financing costs(10,117)Net proceeds from the issuance of common stock and exercise of options32,253397,569Dividends paid on common and preferred stock(238,467)(211,067)Issuance of noncontrolling interests987181Distributions to noncontrolling interests(3,754)(3,912)Net cash provided by (used in) financing activities(357,116)158,597	Issuance of senior unsecured notes		450,000		
Deferred financing costs(10,117)Net proceeds from the issuance of common stock and exercise of options32,253397,569Dividends paid on common and preferred stock(238,467)(211,067)Issuance of noncontrolling interests987181Distributions to noncontrolling interests(3,754)(3,912)Net cash provided by (used in) financing activities(357,116)158,597		(150,000)			
Net proceeds from the issuance of common stock and exercise of options32,253397,569Dividends paid on common and preferred stock(238,467)(211,067)Issuance of noncontrolling interests987181Distributions to noncontrolling interests(3,754)(3,912)Net cash provided by (used in) financing activities(357,116)158,597	Repayments of mortgage debt	(12,135)	(10,057		
Dividends paid on common and preferred stock(238,467)(211,067)Issuance of noncontrolling interests987181Distributions to noncontrolling interests(3,754)(3,912)Net cash provided by (used in) financing activities(357,116)158,597	C		· /		
Issuance of noncontrolling interests987181Distributions to noncontrolling interests(3,754)(3,912)Net cash provided by (used in) financing activities(357,116)158,597		32,253	397,569		
Distributions to noncontrolling interests (3,754) (3,912) Net cash provided by (used in) financing activities (357,116) 158,597	Dividends paid on common and preferred stock	(238,467)	(211,067		
Net cash provided by (used in) financing activities (357,116) 158,597			181		
		(3,754)	(3,912		
Net increase (decrease) in cash and cash equivalents (200,126) 313,919	Net cash provided by (used in) financing activities	(357,116)			
	Net increase (decrease) in cash and cash equivalents	(200,126)	313,919		

Cash and cash equivalents, beginning of period	247,673	33,506
Cash and cash equivalents, end of period	\$ 47,547	\$ 347,425

See accompanying Notes to the Condensed Consolidated Financial Statements.

Table of Contents

HCP, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

(1) Business

HCP, Inc., an S&P 500 company, together with its consolidated entities (collectively, HCP or the Company), invests primarily in real estate serving the healthcare industry in the United States (U.S.). The Company is a Maryland corporation and was organized to qualify as a self-administered real estate investment trust (REIT) in 1985. The Company is headquartered in Long Beach, California, with offices in Nashville, Tennessee and San Francisco, California. The Company acquires, develops, leases, manages and disposes of healthcare real estate, and provides financing to healthcare providers. The Company s portfolio is comprised of investments in the following five healthcare segments: (i) senior housing, (ii) post-acute/skilled nursing, (iii) life science, (iv) medical office and (v) hospital. The Company makes investments within the healthcare segments using the following five investment products: (i) properties under lease, (ii) debt investments, (iii) developments and redevelopments, (iv) investment management and (v) investments in senior housing operations utilizing the structure permitted by the Housing and Economic Recovery Act of 2008, which is commonly referred to as RIDEA.

(2) Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information. Management is required to make estimates and assumptions in the preparation of financial statements in conformity with GAAP. These estimates and assumptions affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from management s estimates.

The condensed consolidated financial statements include the accounts of HCP, its wholly-owned subsidiaries and joint ventures or variable interest entities (VIEs) that it controls through voting rights or other means. Intercompany transactions and balances have been eliminated upon consolidation. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the Company's financial position, results of operations and cash flows have been included. Operating results for the three months ended March 31, 2013 are not necessarily indicative of the results that may be expected for the year ending December 31, 2013. The accompanying unaudited interim financial information should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2012 included in the Company's Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC).

Certain amounts in the Company s condensed consolidated financial statements have been reclassified for prior periods to conform to the current period presentation. Assets sold or held for sale and associated liabilities have been reclassified on the condensed consolidated balance sheets

8
In July 2012, the FASB issued Accounting Standards Update No. 2012-01, <i>Continuing Care Retirement Communities Refundable Advance Fees</i> (ASU 2012-01). This update clarifies the situations in which recognition of deferred revenue for refundable advance fees is appropriate. The adoption of ASU 2012-01 on January 1, 2013 did not have a material impact on the Company s consolidated financial position or results of operations.
In February 2013, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2013-02, Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income (ASU 2013-02). This update requires an entity to provide information about the amounts reclassified out of accumulated other comprehensive income by component. In addition, an entity is required to present, either on the face of the statement where net income is presented or in the notes, significant amounts reclassified out of accumulated other comprehensive income by the respective line items of net income. The adoption of ASU 2013-02 on January 1, 2013 did not have a material impact on the Company s consolidated financial position or results of operations.
Recent Accounting Pronouncements
Transaction costs related to acquisitions of businesses, including properties, are expensed as incurred.
Acquisition Costs
and the related operating results reclassified from continuing to discontinued operations on the condensed consolidated statements of income (see Note 4).

m	. 1		c	\sim			
Tal	hl	e	Ωt	(:(าท	te	nts

(3) Real Estate Property Investments

During the three months ended March 31, 2013 and 2012, the Company funded an aggregate of \$42 million and \$30 million, respectively, for construction, tenant and other capital improvement projects, primarily in its senior housing, life science and medical office segments.

\$1.73 Billion Senior Housing Portfolio Acquisition (the Blackstone JV Acquisition)

During the first quarter of 2013 and fourth quarter of 2012, the Company acquired 133 senior housing communities for \$1.73 billion from a joint venture between Emeritus Corporation (Emeritus) and Blackstone Real Estate Partners VI, an affiliate of the Blackstone Group (the Blackstone JV). Located in 29 states, the portfolio encompasses a diversified care mix of 61% assisted living, 25% independent living, 13% memory care and 1% skilled nursing based on units. Based on operating performance at closing, the 133 communities consisted of 99 that were stabilized and 34 that were in lease-up. The transaction closed in two stages: (i) 129 senior housing facilities during the fourth quarter of 2012 for \$1.7 billion; and (ii) four senior housing facilities during the first quarter of 2013 for \$38 million. The Company paid \$1.73 billion in cash consideration and assumed \$13 million of mortgage debt to acquire: (i) real estate with a fair value of \$1.57 billion, (ii) intangible assets with a fair value of \$174 million; and (iii) assumed intangible liabilities with a fair value of \$4 million. As of March 31, 2013, the purchase price allocation is preliminary, and the final purchase price allocation will be determined pending the receipt of information necessary to complete the valuation of certain assets and liabilities, which may result in changes from the initial estimates.

Emeritus operates the communities pursuant to a new triple-net master lease for 128 properties (the Master Lease) and five individual leases, all guaranteed by Emeritus (together, the Leases). The Leases provide aggregate contractual rent in the first year of \$105.8 million. The contractual rent will increase annually by the greater of the percentage increase in the Consumer Price Index (CPI) or 3.7% on average over the initial five years, and thereafter by the greater of CPI or 3.0% for the remaining initial lease term. At the beginning of the sixth lease year, rent on the 34 lease-up properties will increase to the greater of the percentage increase in CPI or fair market, subject to a floor of 103% and a cap of 130% of the prior year s rent.

The Master Lease properties are grouped into three pools that share comparable characteristics. The Leases have initial terms of 14 to 16 years. Emeritus has two extension options, which, if exercised, will provide for lease terms of 30 to 35 years.

Concurrent with the acquisition, Emeritus purchased nine communities from the Blackstone JV, for which the Company provided secured debt financing of \$52 million with a four-year term. The loan is secured by the underlying real estate and is prepayable at Emeritus option. The interest rate on the loan was initially 6.1% and will gradually increase during its four year term to 6.8%.

Pro Forma Results of Operations

The following unaudited pro forma consolidated results of operations for the three months ended March 31, 2012 assume that the Blackstone JV Acquisition was completed as of January 1, 2012 (in thousands, except per share amounts):

Revenues	\$ 482,277
Net income	204,408
Net income applicable to HCP, Inc.	201,224
Basic earnings per common share	0.43
Diluted earnings per common share	0.43

(4) Dispositions of Real Estate and Discontinued Operations

During the three months ended March 31, 2012, the Company sold a medical office building for \$7 million.

At March 31, 2012, three properties were classified as held for sale, with a combined aggregate carrying value of \$98 million. There were no properties classified as held for sale or reported as discontinued operations as of or during the three months ended March 31, 2013.

The following table summarizes operating loss from discontinued operations and gain on sales of real estate included in discontinued operations for the three months ended March 31, 2012 (dollars in thousands):

Rental and related revenues	\$ 3,430
Depreciation and amortization expenses	2,996
Operating expenses	18
Other expense, net	901
Net loss before gain on sales of real estate	\$ (485)
Gain on sales of real estate, net of income taxes	\$ 2,856
Number of properties included in discontinued operations	4

(5) Net Investment in Direct Financing Leases

The components of net investment in direct financing leases (DFLs) consisted of the following (dollars in thousands):

	March 31, 2013	December 31, 2012
Minimum lease payments receivable(1)	\$ 25,085,037	\$ 25,217,520
Estimated residual values	4,010,514	4,010,514
Less unearned income	(22,174,130)	(22,346,641)
Net investment in direct financing leases	\$ 6,921,421	6,881,393
Properties subject to direct financing leases	361	361

⁽¹⁾ The minimum lease payments receivable are primarily attributable to HCR ManorCare, Inc. (HCR ManorCare) (\$23.9 billion and \$24.0 billion at March 31, 2013 and December 31, 2012, respectively). The triple-net master lease with HCR ManorCare provides for annual rent of \$506 million beginning April 1, 2013 (prior to April 1, 2013, annual rent was \$489 million). The rent increases by 3.5% per year over the next three years and by 3% for the remaining portion of the initial lease term. The properties are grouped into four pools, and HCR ManorCare has a one-time extension option for each pool with rent increased for the first year of the extension option to the greater of fair market rent or a 3% increase over the rent for the prior year. Including the extension options, which the Company determined to be bargain renewal options, the four leased pools had total initial available terms ranging from 23 to 35 years.

Certain leases contain provisions that allow the tenants to elect to purchase the properties during or at the end of the lease terms for the aggregate initial investment amount plus adjustments, if any, as defined in the lease agreements. Certain leases also permit the Company to require the tenants to purchase the properties at the end of the lease terms.

(6) Loans Receivable

The following table summarizes the Company s loans receivable (in thousands):

	eal Estate Secured	rch 31, 2013 Other Secured	Total	Real Estate Secured	Dece	ember 31, 2012 Other Secured	Total
Mezzanine	\$	\$ 145,150	\$ 145,150	\$	\$	145,150	\$ 145,150
Other	163,008		163,008	147,264			147,264
Unamortized discounts, fees							
and costs		(2,878)	(2,878)			(2,974)	(2,974)
Allowance for loan losses		(13,410)	(13,410)			(13,410)	(13,410)
	\$ 163,008	\$ 128,862	\$ 291,870	\$ 147,264	\$	128,766	\$ 276,030

Tandem Health Care Loan

On July 31, 2012, the Company closed a mezzanine loan facility to lend up to \$205 million to Tandem Health Care (Tandem), an affiliate of Formation Capital, as part of the recapitalization of a post-acute/skilled nursing portfolio. The Company funded \$100 million (the First Tranche) at closing and has a commitment to fund an additional \$105 million (the Second Tranche) through August 2013. The Second Tranche will be used to repay debt senior to the Company s loan. At closing, the loan was subordinate to \$400 million in senior mortgage debt and \$137 million in senior mezzanine debt. The loan bears interest at a fixed rate of 12% and 14% per annum for the First and Second Tranche, respectively. The facility has a total term of up to 63 months from the initial closing, is prepayable at the borrower s option and is secured by real estate partnership interests.

Delphis Operations, L.P. Loan

The Company holds a secured term loan made to Delphis Operations, L.P. (Delphis or the Borrower) that is collateralized by all of the assets of the Borrower. The Borrower s collateral is comprised primarily of interests in partnerships operating surgical facilities, some of which are on the premises of properties owned by the Company or HCP Ventures IV, LLC, an unconsolidated joint venture of the Company. In December 2009, the Company determined that the loan was impaired. Further, in January 2011 the Company placed the loan on cost-recovery status, whereby accrual of interest income was suspended and any payments received from the Borrower are applied to reduce the recorded investment in the loan.

As part of a March 2012 agreement (the 2012 Agreement) between Delphis, certain past and current principals of Delphis and the Cirrus Group, LLC (the Guarantors), and the Company, the Company agreed, among other things, to allow the distribution of \$1.5 million to certain of the Guarantors from funds generated from sales of assets that were pledged as additional collateral for this loan. Further, the Company, as part of the 2012 Agreement, agreed to provide financial incentives to the Borrower regarding the liquidation of the primary collateral assets for this loan.

Pursuant to the 2012 Agreement, the Company received the remaining cash (\$4.8 million, after reducing this amount by \$0.5 million for related legal expenses) and other consideration (\$2.1 million) of \$6.9 million from the Guarantors. In addition, during 2012 the Company received \$38.1 million in net proceeds from the sales of two of the primary collateral assets, which proceeds, together with the cash payments and other consideration, were applied to reduce the carrying value of the loan. At both March 31, 2013 and December 31, 2012, the carrying value of the loan was \$30.7 million. At March 31, 2013, the Company believes the fair value of the collateral supporting this loan is in excess of its carrying value.

(7) Investments in and Advances to Unconsolidated Joint Ventures

The Company owns interests in the following entities that are accounted for under the equity method at March 31, 2013 (dollars in thousands):

Entity(1)	Properties/Segment	Investment(2)	Ownership%
HCR ManorCare	post-acute/skilled nursing operations	\$ 88,827	9.5(3)
HCP Ventures III, LLC	13 medical office	7,410	30
HCP Ventures IV, LLC	54 medical office and 4 hospital	31,480	20
HCP Life Science(4)	4 life science	68,287	50-63
Horizon Bay Hyde Park, LLC	1 senior housing	6,581	72
Suburban Properties, LLC	1 medical office	7,044	67
Advances to unconsolidated joint ventures, net		181	
		\$ 209,810	
Edgewood Assisted Living Center, LLC	1 senior housing	\$ (704)	45
Seminole Shores Living Center, LLC	1 senior housing	(428)	50
		\$ (1,132)	

⁽¹⁾ These entities are not consolidated because the Company does not control, through voting rights or other means, the joint ventures.

- (2) Represents the carrying value of the Company s investment in the unconsolidated joint venture.
- (3) Presented after adjusting the Company s 9.9% ownership for the dilution of certain of HCR ManorCare s outstanding employee equity awards.
- (4) Includes three unconsolidated joint ventures between the Company and an institutional capital partner for which the Company is the managing member. HCP Life Science includes the following partnerships: (i) Torrey Pines Science Center, LP (50%); (ii) Britannia Biotech Gateway, LP (55%); and (iii) LASDK, LP (63%).

Summarized combined financial information for the Company s unconsolidated joint ventures follows (in thousands):

	March 31, 2013	December 31, 2012
Real estate, net	\$ 3,706,411	\$ 3,731,740
Goodwill and other assets, net	5,875,013	5,734,318
Total assets	\$ 9,581,424	\$ 9,466,058
Capital lease obligations and mortgage debt	\$ 6,844,859	\$ 6,875,932
Accounts payable	1,108,324	971,095
Other partners capital	1,445,199	1,435,885
HCP s capital(1)	183,042	183,146
Total liabilities and partners capital	\$ 9,581,424	\$ 9,466,058

⁽¹⁾ The combined basis difference of the Company s investments in these joint ventures of \$25 million, as of March 31, 2013, is primarily attributable to goodwill, real estate, capital lease obligations, deferred tax assets and lease related net intangibles.

	Three Months Ended March 31,				
	2013		2012		
Total revenues	\$ 1,093,374	\$	1,044,509		
Net income	10,584		1,125		
HCP s share in earning (1)	14,801		13,675		
Fees earned by HCP	443		493		
Distributions received by HCP	1,371		3,629		

⁽¹⁾ The Company s joint venture interest in HCR ManorCare is accounted for using the equity method and results in an ongoing reduction of DFL income, proportional to HCP s ownership in HCR ManorCare. The Company recorded a reduction of \$15.9 million and \$14.7 million for the three months ended March 31, 2013 and 2012, respectively. Further, the Company s share of earnings from HCR ManorCare (equity income) increases for the corresponding reduction of related lease expense recognized at the HCR ManorCare level.

(8) Intangibles

At March 31, 2013 and December 31, 2012, intangible lease assets, comprised of lease-up intangibles, above market tenant lease intangibles and below market ground lease intangibles, were \$797 million and \$794 million, respectively. At March 31, 2013 and December 31, 2012, the accumulated amortization of intangible assets was \$259 million and \$241 million, respectively.

At both March 31, 2013 and December 31, 2012, intangible lease liabilities, comprised of below market lease intangibles and above market ground lease intangible liabilities were \$199 million. At March 31, 2013 and December 31, 2012, the accumulated amortization of intangible liabilities was \$97 million and \$93 million, respectively.

(9) Other Assets

The Company s other assets consisted of the following (in thousands):

	March 31, 2013	December 31, 2012
Straight-line rent assets, net of allowance of \$33,767 and \$33,521, respectively	\$ 323,513	\$ 306,294
Marketable debt securities(1)	208,214	222,809
Leasing costs, net	93,678	93,763
Deferred financing costs, net	42,944	45,490
Goodwill	50,346	50,346
Marketable equity securities		24,829
Other(2)	58,158	44,989
Total other assets	\$ 776,853	\$ 788,520

⁽¹⁾ Represents £136.9 million of Four Seasons senior unsecured notes translated into U.S. dollars (see below for additional information).

(2) Includes a \$5.4 million allowance for losses related to accrued interest receivable on the Delphis loan, which accrued interest is included in other assets. At both March 31, 2013 and December 31, 2012, the carrying value of interest accrued related to the Delphis loan was zero. See Note 6 for additional information about the Delphis loan and the related impairment. At March 31, 2013 and December 31, 2012, includes a loan receivable of \$8 million and \$10 million, respectively, from HCP Ventures IV, LLC, an unconsolidated joint venture (see Note 7 for additional information) with an interest rate of 12% which matures in May 2014. The loan is secured by HCP s joint venture partner s 80% partnership interest in the joint venture.

During the three months ended March 31, 2013, the Company realized gains from the sale of marketable equity securities of \$11 million, which were included in other income, net. At December 31, 2012, the fair value and adjusted cost basis of the marketable equity securities were \$24.8 million and \$17.1 million, respectively. The marketable equity securities were classified as available-for-sale.

Four Seasons Health Care Senior Unsecured Notes

On June 28, 2012, the Company purchased senior unsecured notes with an aggregate par value of £138.5 million at a discount for £136.8 million (\$214.9 million). The notes were issued by Elli Investments Limited, a subsidiary of Terra Firma, a European private equity firm, as part of its financing for the acquisition of Four Seasons Health Care, an elderly and specialist care provider in the United Kingdom. The notes mature in June 2020 and are non-callable through June 2016. The notes bear interest on their par value at a fixed rate of 12.25% per annum, with an original issue discount resulting in a yield to maturity of 12.5%. This investment was financed by a GBP denominated unsecured term loan that is discussed in Note 10. These senior unsecured notes are accounted for as marketable debt securities and classified as held-to-maturity.

12

Edgar Filling. Flor , INO Form 10-Q
Table of Contents
(10) Debt
Bank Line of Credit and Term Loan
The Company s \$1.5 billion unsecured revolving line of credit facility (the Facility) matures on March 2016 and contains a one-year extension option. Borrowings under the Facility accrue interest at LIBOR plus a margin that depends on the Company s debt ratings. The Company pays a facility fee on the entire revolving commitment that depends upon its debt ratings. Based on the Company s debt ratings at March 31, 2013, the margin on the Facility was 1.075%, and the facility fee was 0.175%. The Facility also includes a feature that will allow the Company to increase the borrowing capacity by an aggregate amount of up to \$500 million, subject to securing additional commitments from existing lenders or new lending institutions. At March 31, 2013, the Company had \$14 million outstanding under the Facility.
On July 30, 2012, the Company entered into a credit agreement with a syndicate of banks for a £137 million (\$208 million at March 31, 2013) four-year unsecured term loan (the Term Loan) that accrues interest at a rate of GBP LIBOR plus 1.20%, based on the Company s current debt ratings. Concurrent with the closing of the Term Loan, the Company entered into a four-year interest rate swap contract that fixes the interest rate of the Term Loan at 1.81%, subject to adjustments based on the Company s debt ratings. The Term Loan contains a one-year committed extension option.
The Facility and Term Loan contain certain financial restrictions and other customary requirements, including cross-default provisions to other indebtedness. Among other things, these covenants, using terms defined in the agreements (i) limit the ratio of Consolidated Total Indebtedness to Consolidated Total Asset Value to 60%, (ii) limit the ratio of Secured Debt to Consolidated Total Asset Value to 30%, (iii) limit the ratio of Unsecured Debt to Consolidated Unencumbered Asset Value to 60%, (iv) require a minimum Fixed Charge Coverage ratio of 1.5 times and (v) require a formula-determined Minimum Consolidated Tangible Net Worth of \$9.2 billion at March 31, 2013. At March 31, 2013, the Company was in compliance with each of these restrictions and requirements of the Facility and Term Loan.
Senior Unsecured Notes
At March 31, 2013, the Company had senior unsecured notes outstanding with an aggregate principal balance of \$6.6 billion. At March 31, 2013, interest rates on the notes ranged from 1.25% to 6.98% with a weighted average effective interest rate of 5.10% and a weighted average maturity of six years. Discounts and premiums are amortized to interest expense over the term of the related senior unsecured notes. The senior unsecured notes contain certain covenants including limitations on debt, cross-acceleration provisions and other customary terms. The Company believes it was in compliance with these covenants at March 31, 2013.
On February 28, 2013, the Company repaid \$150 million of maturing 5.625% senior unsecured notes.

On November 19, 2012, the Company issued \$800 million of 2.625% senior unsecured notes due in 2020. The notes were priced at 99.7% of the

principal amount with an effective yield to maturity of 2.7%; net proceeds from this offering were \$793 million.

On July 23, 2012, the Company issued \$300 million of 3.15% senior unsecured notes due in 2022. The notes were priced at 98.9% of the principal amount with an effective yield to maturity of 3.3%; net proceeds from the offering were \$294 million.

On June 25, 2012, the Company repaid \$250 million of maturing 6.45% senior unsecured notes. The senior unsecured notes were repaid with proceeds from the Company s June 2012 common stock offering.

On January 23, 2012, the Company issued \$450 million of 3.75% senior unsecured notes due in 2019. The notes were priced at 99.5% of the principal amount with an effective yield to maturity of 3.8%; net proceeds from the offering were \$444 million.

Mortgage Debt

At March 31, 2013, the Company had \$1.7 billion in aggregate principal amount of mortgage debt outstanding that is secured by 139 healthcare facilities (including redevelopment properties) with a carrying value of \$2.1 billion. At March 31, 2013, interest rates on the mortgage debt ranged from 1.54% to 8.69% with a weighted average effective interest rate of 6.13% and a weighted average maturity of three years.

Mortgage debt generally requires monthly principal and interest payments, is collateralized by real estate assets and is generally non-recourse. Mortgage debt typically restricts transfer of the encumbered assets, prohibits additional liens, restricts prepayment, requires payment of real estate taxes, requires maintenance of the assets in good condition, requires maintenance of insurance on the assets and includes conditions to obtain lender consent to enter into or terminate material leases. Some of the mortgage debt is also cross-collateralized by multiple assets and may require tenants or operators to maintain compliance with the applicable leases or operating agreements of such real estate assets.

Other Debt

At March 31, 2013, the Company had \$79 million of non-interest bearing life care bonds at two of its CCRCs and non-interest bearing occupancy fee deposits at two of its senior housing facilities, all of which were payable to certain residents of the facilities (collectively, Life Care Bonds). The Life Care Bonds are refundable to the residents upon the termination of the contract or upon the successful resale of the unit.

Debt Maturities

The following table summarizes the Company s stated debt maturities and scheduled principal repayments at March 31, 2013 (in thousands):

Year	Line of Credit	Ter	rm Loan(1)	Senior Unsecured Notes	Mortgage Debt	Total(2)
2013 (Nine months)	\$	\$		\$ 400,000	\$ 283,104 \$	683,104
2014				487,000	180,221	667,221
2015				400,000	308,611	708,611
2016	14,000		208,213	900,000	291,941	1,414,154
2017				750,000	550,698	1,300,698
Thereafter				3,650,000	73,468	3,723,468
	14,000		208,213	6,587,000	1,688,043	8,497,256
(Discounts) and premiums, net				(23,251)	(7,251)	(30,502)
	\$ 14,000	\$	208,213	\$ 6,563,749	\$ 1,680,792 \$	8,466,754

⁽¹⁾ Represents £137 million translated into U.S. dollars.

(11) Commitments and Contingencies

Legal Proceedings

From time to time, the Company is a party to legal proceedings, lawsuits and other claims that arise in the ordinary course of the Company s business. The Company is not aware of any legal proceedings or claims that it believes may have, individually or taken together, a material adverse effect on the Company s business, prospects, financial condition, results of operations or cash flows. The Company s policy is to expense legal costs as they are incurred.

⁽²⁾ Excludes \$79 million of other debt that represents the Life Care Bonds that have no scheduled maturities.

Concentration of Credit Risk

Concentrations of credit risks arise when a number of operators, tenants or obligors related to the Company s investments are engaged in similar business activities, or activities in the same geographic region, or have similar economic features that would cause their ability to meet contractual obligations, including those to the Company, to be similarly affected by changes in economic conditions. The Company regularly monitors various segments of its portfolio to assess potential concentrations of risks. The Company does not have significant foreign operations.

The following table provides information regarding the Company s concentrations with respect to certain operators; the information provided is presented for the gross assets and revenues that are associated with certain operators as percentages of the respective segment s and total Company s gross assets and revenues:

Segment Concentrations:

	Percentage of Senior Housing Gross Assets		Percentag Senior Housing	,
	March 31,	December 31,	Three Months End	ed March 31,
Operators	2013	2012	2013	2012
Emeritus	35%	35%	35%	21%
Sunrise Senior Living (Sunrise)(1)	17	17	13	16
HCR ManorCare	11	11	10	12
Brookdale Senior Living (Brookdale)(2)	10	11	12	14

	8	Percentage of Post-Acute/ Skilled Nursing Gross Assets		ost-Acute/ Revenues
	March 31,	December 31,	Three Months End	ed March 31,
Operators	2013	2012	2013	2012
HCR ManorCare	89%	89%	87%	93%

14

Total Company Concentrations:

	Percentage of Total Company Gross Assets		Percentag Total Company	,
	March 31,	December 31,	Three Months End	ed March 31,
Operators	2013	2012	2013	2012
HCR ManorCare	32%	31%	28%	31%
Emeritus	14	13	13	7
Sunrise(1)	7	7	5	5
Brookdale(2)	4	4	4	5

⁽¹⁾ Certain of the Company s properties are leased to tenants who have entered into management contracts with Sunrise to operate the respective property on their behalf. The Company s concentration of gross assets includes properties directly leased to Sunrise and properties that are managed by Sunrise on behalf of third party tenants.

HCR ManorCare s summarized condensed consolidated financial information follows (in millions):

	M	(arch 31, 2013	December 31, 2012
Real estate and other property, net	\$	3,030.7	3,046.6
Cash and cash equivalents		157.8	120.5
Deferred income taxes		1,622.3	1,627.1
Goodwill and intangible assets, net		3,243.7	3,243.8
Other assets, net		778.0	754.5
Total assets	\$	8,832.5	8,792.5
Debt and financing obligations	\$	6,348.7	6,374.6
Accounts payable and accrued liabilities		1,073.7	1,019.8
Total liabilities		7,422.4	7,394.4
Redeemable preferred stock		2.1	2.1
Total equity		1,408.0	1,396.0
Total liabilities and equity	\$	8,832.5	8,792.5

	Three Months Ended March 31,				
		2013		2012	
Revenues:					
Revenues	\$	1,068.7	\$	1,041.2	
Costs and expenses:					
Operating, general and administrative		912.4		885.4	
Depreciation and amortization		37.3		42.0	

⁽²⁾ At March 31, 2013 and December 31, 2012, Brookdale percentages exclude \$700 million and \$692 million, respectively, of senior housing assets related to 21 senior housing facilities that Brookdale operates on the Company s behalf under a RIDEA structure. Assuming that these assets were attributable to Brookdale, the percentage of segment and total assets for Brookdale would be 20% and 8%, respectively, at both March 31, 2013 and December 31, 2012. For the three months ended March 31, 2013 and 2012, Brookdale percentages exclude \$37 million and \$35 million, respectively, of senior housing revenues related to these facilities. Assuming that these revenues were attributable to Brookdale, the percentage of segment and total revenues for Brookdale would be 31% and 11% respectively, for the three months ended March 31, 2013. Assuming that these revenues were attributable to Brookdale, the percentage of segment and total revenues for Brookdale would be 37% and 12% respectively, for the three months ended March 31, 2012.

Edgar Filing: HCP, INC. - Form 10-Q

Interest expense	104.4	106.3
Total costs and expenses	1,054.1	1,033.7
Other income, net	0.7	1.7
Income before income taxes and equity income from unconsolidated		
joint ventures	15.3	9.2
Income taxes and equity income from unconsolidated joint ventures	(3.6)	(2.9)
Net income	\$ 11.7	\$ 6.3

	Three Months Ended March 31,			/
	2	2013		2012
Net cash provided by operating activities	\$	88.6	\$	22.1
Cash flows from investing activities:				
Acquisitions of property and equipment		(21.2)		(24.9)
Purchase of securities and other		(4.1)		(2.2)
Net cash used in investing activities		(25.3)		(27.1)
Cash flows from financing activities:				
Repayments of debt and financing obligations		(26.0)		(19.6)
Net increase (decrease) in cash and cash equivalents		37.3		(24.6)
Cash and cash equivalents, beginning of period		120.5		186.5
Cash and cash equivalents, end of period	\$	157.8	\$	161.9

To mitigate the credit risk of leasing properties to certain senior housing and post-acute/skilled nursing operators, leases with operators are often combined into portfolios that contain cross-default terms, so that if a tenant of any of the properties in a portfolio defaults on its obligations under its lease, the Company may pursue its remedies under the lease with respect to any of the properties in the portfolio. Certain portfolios also contain terms whereby the net operating profits of the properties are combined for the purpose of securing the funding of rental payments due under each lease.

Tah	le	οf	Con	tents
1 au	ı	OI.	\sim	wiito

Credit Enhancement Guarantee

Certain of the Company s senior housing facilities serve as collateral for \$116 million of debt (maturing May 1, 2025) that is owed by a previous owner of the facilities. This indebtedness is guaranteed by the previous owner who has an investment grade credit rating. These senior housing facilities, which are classified as DFLs, had a carrying value of \$375 million as of March 31, 2013.

(12) Equity

Preferred Stock

On April 23, 2012, the Company redeemed all of its outstanding preferred stock consisting of 4,000,000 shares of its 7.25% Series E preferred stock and 7,820,000 shares of its 7.10% Series F preferred stock. The shares of Series E and Series F preferred stock were redeemed at a price of \$25 per share, or \$295.5 million in aggregate, plus all accrued and unpaid dividends to the redemption date. As a result of the redemption, which was announced on March 22, 2012, the Company incurred a charge of \$10.4 million during the three months ended March 31, 2012 related to the original issuance costs of the preferred stock (this charge is presented as an additional preferred stock dividend in the Company s condensed consolidated statements of income).

Common Stock

The following table lists the common stock cash dividends declared by the Company in 2013:

Declaration Date	Record Date	Amount Per Share	Dividend Payable Date
January 24	February 4	\$ 0.525	February 19
April 25	May 6	0.525	May 21

In October 2012, the Company completed a \$979 million offering of 22 million shares of common stock at a price of \$45.50, which proceeds were primarily used to fund the Blackstone JV Acquisition.

In June 2012, the Company completed a \$376 million offering of 8.97 million shares of common stock at a price of \$41.88 per share, which proceeds were primarily used to repay \$250 million of maturing senior unsecured notes.

In March 2012, the Company completed a \$359 million offering of 9.0 million shares of common stock at a price of \$39.93 per share, which proceeds were primarily used to redeem all outstanding shares of the Company s preferred stock.

The following is a summary of the Company s other common stock issuances (shares in thousands):

	Three Months Ended March 31,		
	2013	2012	
Dividend Reinvestment and Stock Purchase Plan	382	210	
Conversion of DownREIT units(1)	51	36	
Exercise of stock options	796	1,412	
Vesting of restricted stock units(2)	17	314	

- (1) Non-managing member LLC units.
- (2) Issued under the Company s 2006 Performance Incentive Plan.

Accumulated Other Comprehensive Loss

The following is a summary of the Company s accumulated other comprehensive loss (in thousands):

	March 31, 2013	December 31, 2012
Unrealized gains on available for sale securities	\$ \$	7,776
Unrealized losses on cash flow hedges, net	(12,860)	(18,452)
Supplemental Executive Retirement Plan minimum liability	(3,095)	(3,150)
Cumulative foreign currency translation adjustment	(649)	(827)
Total accumulated other comprehensive loss	\$ (16,604) \$	(14,653)

Noncontrolling Interests

At March 31, 2013, there were four million DownREIT units outstanding in four LLCs, for which the Company is the managing member. At March 31, 2013, the carrying and fair values of these DownREIT units were \$186 million and \$301 million, respectively.

(13) Segment Disclosures

The Company evaluates its business and makes resource allocations based on its five business segments: (i) senior housing, (ii) post-acute/skilled nursing, (iii) life science, (iv) medical office and (v) hospital. Under the senior housing, post-acute/skilled nursing, life science and hospital segments, the Company invests or co-invests primarily in single operator or tenant properties, through the acquisition and development of real estate and by debt issued by operators in these sectors. Under the medical office segment, the Company invests or co-invests through the acquisition and development of medical office buildings (MOBs) that are leased under gross, modified gross or triple-net leases, generally to multiple tenants, and which generally require a greater level of property management. The accounting policies of the segments are the same as those described in Note 2 to the Consolidated Financial Statements for the year ended December 31, 2012 in the Company s Annual Report on Form 10-K filed with the SEC. There were no intersegment sales or transfers during the three months ended March 31, 2013 and 2012 The Company evaluates performance based upon property net operating income from continuing operations (NOI), adjusted NOI and interest income of the combined investments in each segment.

Non-segment assets consist primarily of corporate assets including cash, restricted cash, accounts receivable, net, marketable equity securities, deferred financing costs and, if any, real estate held-for-sale. Interest expense, depreciation and amortization and non-property specific revenues and expenses are not allocated to individual segments in determining the Company s performance measure. See Note 11 for other information regarding concentrations of credit risk.

Summary information for the reportable segments follows (in thousands):

For the three months ended March 31, 2013:

		Rental	Res	sident Fees	Interest	Investme Managem		Total			Adjusted NOI(2)
Segments	Re	venues(1)	an	d Services	Income	Fee Inco		Revenues	NOI(2)	((Cash NOI)
Senior housing	\$	149,091	\$	36,891	\$ 2,401	\$		\$ 188,383	\$ 161,591	\$	143,193
Post-acute/skilled		136,103			9,985			146,088	135,456		116,158
Life science		73,330					1	73,331	59,947		56,340
Medical office		87,255				4	442	87,697	52,959		51,671
Hospital		20,770						20,770	19,882		19,432
Total	\$	466,549	\$	36,891	\$ 12,386	\$	443	\$ 516,269	\$ 429,835	\$	386,794

For the three months ended March 31, 2012:

		Rental		sident Fees	Interest	Investment Management		Total			Adjusted NOI(2)
Segments	Re	venues(1)	an	d Services	Income	Fee Income		Revenues	NOI(2)	((Cash NOI)
Senior housing	\$	113,500	\$	36,179	\$ 282	\$	\$	149,961	\$ 128,065	\$	114,648
Post-acute/skilled		133,673			280			133,953	133,473		112,848
Life science		71,830				1		71,831	58,946		59,104
Medical office		79,955				492	2	80,447	48,250		46,921

Edgar Filing: HCP, INC. - Form 10-Q

Hospital	19,378		257				19,635	18,448	17,893
Total	\$ 418,336	\$ 36,179 \$	819	\$ 4	93 \$	S	455,827	\$ 387,182	\$ 351,414

⁽¹⁾ Represents rental and related revenues, tenant recoveries and income from DFLs.

The following is a reconciliation of reported net income to NOI and adjusted NOI (in thousands):

	Three Months Ended March 31,					
		2013		2012		
Net income	\$	233,784	\$	196,564		
Interest income		(12,386)		(819)		
Investment management fee income		(443)		(493)		
Interest expense		109,351		103,752		
Depreciation and amortization		104,717		85,280		
General and administrative		20,744		20,089		
Other income, net		(12,012)		(436)		
Income taxes		881		(709)		
Equity income from unconsolidated joint ventures		(14,801)		(13,675)		
Total discontinued operations				(2,371)		
NOI		429,835		387,182		
Straight-line rents		(18,793)		(9,927)		
DFL accretion		(24,170)		(25,622)		
Amortization of above and below market lease intangibles, net		(78)		(697)		
Lease termination fees				(148)		
NOI adjustments related to discontinued operations				626		
Adjusted NOI	\$	386,794	\$	351,414		

⁽²⁾ NOI is a non-GAAP supplemental financial measure used to evaluate the operating performance of real estate. The Company defines NOI as rental and related revenues, including tenant recoveries, resident fees and services, and income from direct financing leases, less property level operating expenses. NOI excludes interest income, investment management fee income, interest expense, depreciation and amortization, general and administrative expenses, litigation settlement, impairments, impairment recoveries, other income, net, income taxes, equity income from and impairments of investments in unconsolidated joint ventures, and discontinued operations. The Company believes NOI provides relevant and useful information because it reflects only income and operating expense items that are incurred at the property level and presents them on an unleveraged basis. Adjusted NOI is calculated as NOI after eliminating the effects of straight-line rents, DFL accretion, amortization of above and below market lease intangibles, and lease termination fees. Adjusted NOI is sometimes referred to as cash NOI. The Company uses NOI and adjusted NOI to make decisions about resource allocations and to assess and compare property level performance. The Company believes that net income is the most directly comparable GAAP measure to NOI. NOI should not be viewed as an alternative measure of operating performance to net income as defined by GAAP because it does not reflect the aforementioned excluded items. Further, the Company s definition of NOI may not be comparable to the definition used by other REITs, as those companies may use different methodologies for calculating NOI.

The Company s total assets by segment were (in thousands):

Segments	March 31, 2013	December 31, 2012
Senior housing	\$ 7,739,727	\$ 7,658,612
Post-acute/skilled nursing	6,098,982	6,080,826
Life science	3,943,454	3,932,397
Medical office	2,664,053	2,661,394
Hospital	729,826	724,999
Gross segment assets	21,176,042	21,058,228
Accumulated depreciation and amortization	(2,079,778)	(1,978,597)
Net segment assets	19,096,264	19,079,631
Other non-segment assets	636,467	835,924
Total assets	\$ 19,732,731	\$ 19,915,555

At March 31, 2013, goodwill of \$50 million was allocated to segment assets as follows: (i) senior housing \$31 million, (ii) post-acute/skilled nursing \$3 million, (iii) medical office \$11 million, and (iv) hospital \$5 million.

(14) Earnings Per Common Share

The following table illustrates the computation of basic and diluted earnings per share (in thousands, except per share amounts):

	Three Months E 2013	arch 31, 2012	
Numerator			
Income from continuing operations	\$ 233,784	\$	194,193
Noncontrolling interests share in continuing operations	(3,199)		(3,184)
Income from continuing operations applicable to HCP, Inc.	230,585		191,009
Preferred stock dividends			(17,006)
Participating securities share in continuing operations	(478)		(1,117)
Income from continuing operations applicable to common shares	230,107		172,886
Discontinued operations			2,371
Net income applicable to common shares	\$ 230,107	\$	175,257
Denominator			
Basic weighted average common shares	453,651		410,018
Dilutive potential common shares	962		1,643
Diluted weighted average common shares	454,613		411,661
Basic earnings per common share			
Income from continuing operations	\$ 0.51	\$	0.42
Discontinued operations			0.01
Net income applicable to common shares	\$ 0.51	\$	0.43
Diluted earnings per common share			
Income from continuing operations	\$ 0.51	\$	0.42

Discontinued operations		0.01
Net income applicable to common shares	\$ 0.51	\$ 0.43

Restricted stock and certain of the Company s performance restricted stock units are considered participating securities, because dividend payments are not forfeited even if the underlying award does not vest, which require the use of the two-class method when computing basic and diluted earnings per share.

Options to purchase approximately 0.5 million and 1.1 million shares of common stock that had an exercise price (including deferred compensation expense) in excess of the average closing market price of the Company s common stock during the three months ended March 31, 2013 and 2012, respectively, were not included in the Company s earnings per share calculations because they are anti-dilutive. Restricted stock and performance restricted stock units representing 0.4 million and 0.5 million shares of

common stock during the three months ended March 31, 2013 and 2012, respectively, were not included because they are anti-dilutive. Additionally, 6.0 million shares issuable upon conversion of 4.0 million DownREIT units during the three months ended March 31, 2013 were not included because they are anti-dilutive. During the three months ended March 31, 2012, 5.9 million shares issuable upon conversion of 4.2 million DownREIT units were not included because they are anti-dilutive.

(15) Supplemental Cash Flow Information

The following table provides supplemental cash flow information (in thousands):

	Three Months E 2013	arch 31, 2012	
Supplemental cash flow information:			
Interest paid, net of capitalized interest	\$ 154,127	\$	137,001
Income taxes paid	75		142
Capitalized interest	4,111		6,683
Supplemental schedule of non-cash investing activities:			
Accrued construction costs	15,029		14,589
Supplemental schedule of non-cash financing activities:			
Preferred stock redemption accrual			296,896
Vesting of restricted stock units	17		314
Cancellation of restricted stock	(6)		(1)
Conversion of non-managing member units into common stock	2,179		1,034
Mortgages and other liabilities assumed with real estate acquisitions	12,728		
Unrealized gains on available-for-sale securities and derivatives			
designated as cash flow hedges, net	6,675		1,580

See additional information regarding supplemental non-cash financing activities related to the preferred stock redemption in Note 12.

(16) Variable Interest Entities

Unconsolidated Variable Interest Entities

At March 31, 2013, the Company leased 48 properties to a total of seven VIE tenants and had an additional investment in a loan to a VIE borrower. The Company has determined that it is not the primary beneficiary of these VIEs. The carrying value and classification of the related assets, liabilities and maximum exposure to loss as a result of the Company s involvement with these VIEs are presented below at March 31, 2013 (in thousands):

VIE Type Asset/Liability Type

	M	aximum Loss		Carrying
		Exposure(1)		Amount
VIE tenants operating leases	\$	1,397,774	Lease intangibles, net and straight-line rent receivables	\$ 615,655
VIE tenants DFLs		911,051	Net investment in DFLs	911,051
Loan senior secured		30,652	Loans receivable, net	30,652

⁽¹⁾ The Company s maximum loss exposure related to the VIE tenants represents the future minimum lease payments over the remaining term of the respective leases, which may be mitigated by re-leasing the properties to new tenants. The Company s maximum loss exposure related to its loan to the VIE represents its current aggregate carrying amount.

As of March 31, 2013, the Company has not provided, and is not required to provide, financial support through a liquidity arrangement or otherwise, to its unconsolidated VIEs, including circumstances in which it could be exposed to further losses (e.g., cash shortfalls).

The Company holds an interest-only, senior secured term loan made to a borrower (Delphis Operations, L.P.) that has been identified as a VIE (see Note 6 for additional information on the Delphis loan). The Company does not consolidate the VIE because it does not have the ability to control the activities that most significantly impact the VIE s economic performance. The loan is collateralized by all of the assets of the borrower (comprised primarily of interests in partnerships that operate surgical facilities, some of which are on the premises of properties owned by the Company or HCP Ventures IV, LLC) and is supported in part by limited guarantees made by certain former and current principals of the borrower. Recourse under certain of these guarantees is limited to the guarantors respective ownership interests in certain entities owning real estate that are pledged to secure such guarantees.

See Notes 5 and 6 for additional description of the nature, purpose and activities of the Company s unconsolidated VIEs and interests therein.

Consolidated Variable Interest Entities

In September 2011, the Company formed a partnership in which it has a 90% ownership interest and a leasing relationship with an entity that operates 21 properties in a RIDEA structure (RIDEA Entity). The Company consolidated this entity as a result of the rights it acquired through the joint venture agreement with Brookdale. In the fourth quarter of 2012, upon the occurrence of a reconsideration event, it was determined that this RIDEA Entity is a VIE and that the Company is the primary beneficiary; therefore, the Company continues to consolidate this entity. The assets and liabilities of this RIDEA Entity substantially consist of cash and cash equivalents, accounts receivable, and accounts payable and accrued liabilities generated from its operating activities. The assets generated by the operating activities of the RIDEA Entity may be used to settle its contractual obligations, which include lease obligations to the Company. The Company is entitled to its ownership share of the RIDEA Entity is assets; however, it does not guarantee its liabilities (or contractual obligations) and is not liable to its general creditors.

(17) Fair Value Measurements

The following table illustrates the Company s financial assets and liabilities measured at fair value on a recurring basis in the condensed consolidated balance sheets. Recognized gains and losses are recorded in other income, net on the Company s condensed consolidated statements of income. During the three months ended March 31, 2013, there were no transfers of financial assets or liabilities within the fair value hierarchy.

The financial assets and liabilities carried at fair value on a recurring basis at March 31, 2013 follow (in thousands):

Financial Instrument	Fa	ir Value	Level 2	Level 3
Currency swap asset(1)	\$	2,490 \$	2,490 \$	
Interest-rate swap liabilities (1)		(12,421)	(12,421)	
Warrants(1)		775		775
	\$	(9,156) \$	(9,931) \$	775

⁽¹⁾ Interest rate and currency swaps as well as common stock warrant fair values are determined based on observable and unobservable market assumptions utilizing standardized derivative pricing models.

(18) Disclosures About Fair Value of Financial Instruments

The carrying values of cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued liabilities are reasonable estimates of fair value because of the short-term maturities of these instruments. The fair values of loans receivable, bank line of credit, term

loan, mortgage debt and other debt are based on rates currently prevailing for similar instruments with similar maturities. The fair values of the marketable debt securities, interest-rate and currency swap contracts as well as common stock warrants are determined based on observable and unobservable market assumptions using standardized pricing models. The fair values of the senior unsecured notes and marketable equity securities are determined utilizing market quotes.

The table below summarizes the carrying amounts and fair values of the Company s financial instruments (in thousands):

	March :	31, 20	13	December 31, 2012					
	Value		Fair Value		Carrying Value		Fair Value		
Loans receivable, net(2)	\$ 291,870	\$	294,724	\$	276,030	\$	279,850		
Marketable debt securities(3)	208,214		226,337		222,809		234,137		
Marketable equity securities(1)					24,829		24,829		
Warrants(3)	775		775		670		670		
Bank line of credit(2)	14,000		14,000						
Term loan(2)	208,213		208,213		222,694		222,694		
Senior unsecured notes(1)	6,563,749		7,303,804		6,712,624		7,432,012		
Mortgage debt(2)	1,680,792		1,763,165		1,676,544		1,771,155		
Other debt(2)	78,836		78,836		81,958		81,958		
Interest-rate swap assets(2)					89		89		
Interest-rate swap liabilities(2)	12,421		12,421		12,699		12,699		
Currency swap asset(2)	2,490		2,490						
Currency swap liabilities(2)					2,641		2,641		

⁽¹⁾ Level 1: Fair value calculated based on quoted prices in active markets.

⁽²⁾ Level 2: Fair value based on quoted prices for similar or identical instruments in active or inactive markets, respectively, or calculated utilizing model derived valuations in which significant inputs or value drivers are observable in active markets.

⁽³⁾ Level 3: Fair value determined based on significant unobservable market inputs using standardized derivative pricing models.

(19) Derivative Financial Instruments

The following table summarizes the Company s outstanding interest-rate and foreign currency swap contracts as of March 31, 2013 (dollars and GBP in thousands):

				Fixed					
		Hedge]	Rate/Buy	Floating/Exchange		Notional/		
Date Entered	Maturity Date	Designation		Amount	Rate Index	Sell Amount		Fa	ir Value(1)
July 2005(2)	July 2020	Cash Flow		3.82%	BMA Swap Index	\$	45,600	\$	(8,189)
November 2008(3)	October 2016	Cash Flow		5.95%	1 Month LIBOR+1.50%	\$	26,900	\$	(3,603)
July 2009(4)	July 2013	Cash Flow		6.13%	1 Month LIBOR+3.65%	\$	13,600	\$	(79)
					1 Month GBP				
July 2012(4)	June 2016	Cash Flow		1.81%	LIBOR+1.20%	£	137,000	\$	(549)
July 2012(5)	June 2016	Cash Flow	\$	79,600	Buy USD/Sell GBP	£	50,700	\$	2,490

⁽¹⁾ Interest-rate and foreign currency swap assets are recorded in other assets, net and interest-rate and foreign currency swap liabilities are recorded in accounts payable and accrued liabilities on the condensed consolidated balance sheets.

- (4) Hedges fluctuations in interest payments on variable-rate secured and unsecured debt due to fluctuations in the underlying benchmark interest rate.
- (5) Currency swap contract (buy USD/sell GBP) hedges the foreign currency exchange risk related to a portion of the Company s forecasted interest receipts on GBP denominated senior unsecured notes. Represents seven foreign exchange contracts to sell £7.2 million at a rate of 1.5695 on various dates between June 2013 and June 2016.

The Company uses derivative instruments to mitigate the effects of interest rate and foreign currency fluctuations on specific forecasted transactions as well as recognized financial obligations or assets. The Company does not use derivative instruments for speculative or trading purposes.

The primary risks associated with derivative instruments are market and credit risk. Market risk is defined as the potential for loss in value of a derivative instrument due to adverse changes in market prices. Utilizing derivative instruments allows the Company to manage the risk of fluctuations in interest and foreign currency rates related to the potential impact these changes could have on future earnings, forecasted cash flows and the fair value of recognized obligations.

Credit risk is the risk that one of the parties to a derivative contract fails to perform or meet their financial obligation. The Company does not obtain collateral associated with its derivative contracts, but monitors the credit standing of its counterparties on a regular basis. Should a counterparty fail to perform, the Company would incur a financial loss to the extent that the associated derivative contract was in an asset

⁽²⁾ Represents three interest-rate swap contracts with an aggregate notional amount of \$45.6 million which hedge fluctuations in interest payments on variable-rate secured debt due to overall changes in hedged cash flows.

⁽³⁾ Acquired in conjunction with mortgage debt assumed related to real estate acquired on December 28, 2010. Hedges fluctuations in interest payments on variable-rate secured debt due to fluctuations in the underlying benchmark interest rate.

position. At March 31, 2013, the Company does not anticipate non-performance by the counterparties to its outstanding derivative contracts.

On July 27, 2012, the Company entered into foreign currency swap contracts to hedge the foreign currency exchange risk related to a portion of the forecasted interest receipts from its GBP denominated senior unsecured notes (see additional discussion of the Four Seasons Health Care Senior Unsecured Notes in Note 9). The cash flow hedge has a fixed USD/GBP exchange rate of 1.5695 (buy \$11.4 million and sell £7.2 million semi-annually) for a portion of its forecasted semi-annual cash receipts denominated in GBP. The foreign currency swap contracts mature through June 2016 (the end of the non-call period of the senior unsecured notes). The fair value of the contracts at March 31, 2013 was \$2.5 million and is included in other assets, net. During the three months ended March 31, 2013, there was no ineffective portion related to this hedge.

On July 27, 2012, the Company entered into an interest-rate swap contract that is designated as hedging the interest payments on its GBP denominated Term Loan due to fluctuations in the underlying benchmark interest rate (see additional discussion of the Term Loan in Note 10). The cash flow hedge has a notional amount of £137 million and expires in June 2016 (the maturity of the Term Loan). The fair value of the contract at March 31, 2013 was a liability of \$0.5 million and is included in accounts payable and accrued liabilities. During the three months ended March 31, 2013, there was no ineffective portion related to this hedge.

Table of Contents

At March 31, 2013, the Company expects that the hedged forecasted transactions for each of the outstanding qualifying cash flow hedging relationships remain probable of occurring and as a result no gains or losses recorded to accumulated other comprehensive loss are expected to be reclassified to earnings.

To illustrate the effect of movements in the interest rate and foreign currency markets, the Company performed a market sensitivity analysis on its outstanding hedging instruments. The Company applied various basis point spreads to the underlying interest rate curves and foreign currency exchange rates of the derivative portfolio in order to determine the instruments—change in fair value. The following table summarizes the results of the analysis performed (dollars in thousands):

		Effects of Change in Interest and Foreign Currency Rates												
			+50 Basis		-50 Basis		+100 Basis		-100 Basis					
Date Entered	Maturity Date	Points			Points		Points	Points						
July 2005	July 2020	\$	1,623	\$	(1,520)	\$	3,195	\$	(3,092)					
November 2008	October 2016		464		(455)		924		(915)					
July 2009	July 2013		16		(20)		34		(38)					
July 2012	June 2016		3,367		(3,263)		6,683		(6,578)					
July 2012	June 2016		(336)		434		(721)		820					

(20) Subsequent Events

On May 2, 2013, the Company acquired approximately \$165 million of debt secured by real estate.

(b)

Item 2. Management s Discussion and Analysis of Financial Condition and Results of Operations

Cautionary Language Regarding Forward-Looking Statements

Statements in this Quarterly Report on Form 10-Q that are not historical factual statements are forward-looking statements. We intend to have our forward-looking statements covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include this statement for purposes of complying with those provisions. Forward-looking statements include, among other things, statements regarding our and our officers intent, belief or expectation as identified by the use of words such as may, will, project, expect, believe, antici estimate, could, would, should and other comparable and derivative terms or the negatives thereof. In addition, we, through plan. officers, from time to time, make forward-looking oral and written public statements concerning our expected future operations, strategies, securities offerings, growth and investment opportunities, dispositions, capital structure changes, budgets and other developments. Readers are cautioned that, while forward-looking statements reflect our good faith belief and reasonable assumptions based upon current information, we can give no assurance that our expectations or forecasts will be attained. Therefore, readers should be mindful that forward-looking statements are not guarantees of future performance and that they are subject to known and unknown risks and uncertainties that are difficult to predict. As more fully set forth under Part I, Item 1A. Risk Factors in our Annual Report on Form 10-K for the fiscal year ended December 31, 2012, factors that may cause our actual results to differ materially from the expectations contained in the forward-looking statements include:

- Changes in global, national and local economic conditions, including a prolonged period of weak economic growth; (a)
- Volatility in the capital markets, including changes in interest rates and the availability and cost of capital;
- Our ability to manage our indebtedness level and changes in the terms of such indebtedness; (c)
- The effect on healthcare providers of the automatic spending cuts enacted by Congress (Sequestration) on entitlement programs, including Medicare, will, unless modified, result in future reductions in reimbursements;
- (e) The ability of our operators, tenants and borrowers to conduct their respective businesses in a manner sufficient to maintain or increase their revenues and to generate sufficient income to make rent and loan payments to us and our ability to recover investments made, if applicable, in their operations;
- The financial weakness of some operators and tenants, including potential bankruptcies and downturns in their businesses, which results in uncertainties regarding our ability to continue to realize the full benefit of such operators and/or tenants leases;

(g) complia	Changes in federal, state or local laws and regulations, including those affecting the healthcare industry that affect our costs of ance or increase the costs, or otherwise affect the operations of our operators, tenants and borrowers;
(h) related	The potential impact of future litigation matters, including the possibility of larger than expected litigation costs, adverse results and developments;
(i) leases;	Competition for tenants and borrowers, including with respect to new leases and mortgages and the renewal or rollover of existing
(j) right to	Our ability to negotiate the same or better terms with new tenants or operators if existing leases are not renewed or we exercise our replace an existing operator or tenant upon default;
(k)	Availability of suitable properties to acquire at favorable prices and the competition for the acquisition and financing of those properties;
(1)	The financial, legal, regulatory and reputational difficulties of significant operators of our properties;
(m) T projecti	The risk that we may not be able to achieve the benefits of investments within expected time-frames or at all, or within expected cost ons;
(n)	The ability to obtain financing necessary to consummate acquisitions on favorable terms;
	23

Table of Contents

(o) authori	The risks associated with our investments in joint ventures and unconsolidated entities, including our lack of sole decision making ty and our reliance on our joint venture partners financial condition and continued cooperation; and
(p)	Changes in the credit ratings on U.S. government debt securities or default or delay in payment by the United States of its obligations.
	as required by law, we undertake no, and hereby disclaim any, obligation to update any forward-looking statements, whether as a resul information, changed circumstances or otherwise.
	Formation set forth in this Item 2 is intended to provide readers with an understanding of our financial condition, changes in financial on and results of operations. We will discuss and provide our analysis in the following order:
•	Executive Summary
•	2013 Transaction Overview
•	Dividends
•	Critical Accounting Policies
•	Results of Operations
•	Liquidity and Capital Resources
•	Funds from Operations (FFO)
•	Off-Balance Sheet Arrangements

• Co	ontractual Obligations
• Inf	flation
• Re	ecent Accounting Pronouncements
Executive Su	mmary
unconsolidate lease, manage investments, i	yland corporation and were organized to qualify as a self-administered real estate investment trust (REIT) that, together with our d joint ventures, invests primarily in real estate serving the healthcare industry in the United States (U.S.). We acquire, develop, and dispose of healthcare real estate, and provide financing to healthcare providers. At March 31, 2013, our portfolio of including properties in our Investment Management Platform, consisted of interests in 1,164 facilities. Our Investment Platform represents the following joint ventures: (i) HCP Ventures III, LLC, (ii) HCP Ventures IV, LLC and (iii) the HCP Life res.
actively redep investments w	strategy is based on three principles: (i) opportunistic investing, (ii) portfolio diversification and (iii) conservative financing. We bloy capital from investments with lower return potential or shorter investment horizons into assets representing longer term with attractive risk-adjusted return potential. We make investments where the expected risk-adjusted return exceeds our cost of rive to capitalize on our operator, tenant and other business relationships to grow our business.
private transac	contemplates acquiring and developing properties on terms that are favorable to us. Generally, we prefer larger, more complex ctions that leverage our management team s experience and our infrastructure. We follow a disciplined approach to enhancing the xisting portfolio, including ongoing evaluation of potential disposition of properties that no longer fit our strategy.
our rents and expenses; how generally related (RIDEA prosuch as real estimates and occurrents).	generate revenue by leasing healthcare properties under long-term leases with fixed and/or inflation indexed escalators. Most of other earned income from leases are received under triple-net leases or leases that provide for substantial recovery of operating every, some of our medical office and life science leases are structured as gross or modified gross leases. Operating expenses are ted to medical office building (MOB) and life science leased properties and senior housing properties managed on our behalf perties). Accordingly, for such MOBs, life science facilities and RIDEA properties, we incur certain property operating expenses, state taxes, repairs and maintenance, property management fees, utilities, employee costs for resident care and insurance. Our ese assets depends, in part, on our ability to (i) increase rental income and other earned income from leases by increasing rental apancy levels; (ii) maximize tenant recoveries given underlying lease structures; and (iii) control operating and other expenses. Our impacted by property specific, market specific, general economic and other conditions.
	24

Table of Contents
2013 Transaction Overview
Investment Transactions
During the quarter ended March 31, 2013, we made investments of \$96 million as follows: (i) \$38 million to purchase the four remaining senior housing facilities from our previously announced Blackstone JV Acquisition; and (ii) \$58 million to fund development and other capital projects, primarily in our life science, medical office and senior housing segments.
During the quarter ended March 31, 2013, we placed into service a 70,000 square feet building located in Mountain View, California that is 100% leased.
Financing Activities
On February 28, 2013, we repaid \$150 million of maturing 5.625% senior unsecured notes.
Dividends
On April 25, 2013, we announced that our Board declared a quarterly common stock cash dividend of \$0.525 per share. The common stock dividend will be paid on May 21, 2013 to stockholders of record as of the close of business on May 6, 2013 and represents an annualized dividend pay rate of \$2.10 per share.
Critical Accounting Policies
The preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires our management to use judgment in the application of accounting policies, including making estimates and assumptions. We base estimates on the best information available to us at the time, our experience and on various other assumptions believed to be reasonable under the circumstances. These estimates

The preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires our management to use judgment in the application of accounting policies, including making estimates and assumptions. We base estimates on the best information available to us at the time, our experience and on various other assumptions believed to be reasonable under the circumstances. These estimates affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. If our judgment or interpretation of the facts and circumstances relating to various transactions or other matters had been different, it is possible that different accounting would have been applied, resulting in a different presentation of our condensed consolidated financial statements. From time to time, we re-evaluate our estimates and assumptions. In the event estimates or assumptions prove to be different from actual results, adjustments are made in subsequent periods to reflect more current estimates and assumptions about matters that are inherently uncertain. A summary of our critical accounting policies is included in our Annual Report on Form 10-K for the year ended December 31, 2012 in Item 7. Management s Discussion and Analysis of Financial Condition and Results of Operations; our critical accounting policies have not changed during 2013.

Results of Operations

We evaluate our business and allocate resources among our five business segments: (i) senior housing, (ii) post-acute/skilled nursing, (iii) life science, (iv) medical office and (v) hospital. Under the senior housing, life science, post-acute/skilled nursing and hospital segments, we invest or co-invest primarily in single operator or tenant properties, through the acquisition and development of real estate, management of operations and by debt issued by operators in these sectors. Under the medical office segment, we invest or co-invest through the acquisition and development of MOBs that are leased under gross, modified gross or triple-net leases, generally to multiple tenants, and which generally require a greater level of property management.

We use net operating income from continuing operations (NOI) and adjusted NOI to assess and compare property level performance, including our same property portfolio (SPP), and to make decisions about resource allocations. We believe these measures provide investors relevant and useful information because they reflect only income and operating expense items that are incurred at the property level and present them on an unleveraged basis. We believe that net income is the most directly comparable GAAP measure to NOI. NOI should not be viewed as an alternative measure of operating performance to net income as defined by GAAP since NOI excludes certain components from net income. Further, NOI may not be comparable to that of other REITs, as they may use different methodologies for calculating NOI. See Note 13 to the Condensed Consolidated Financial Statements for additional segment information and the relevant reconciliations from net income to NOI and adjusted NOI.

Operating expenses are generally related to MOB and life science leased properties and senior housing properties managed on our behalf (RIDEA properties). We generally recover all or a portion of MOB and life science expenses from the tenants (tenant recoveries). The presentation of expenses as operating or general and administrative is based on the underlying nature of the expense. Periodically, we review the classification of expenses between categories and make revisions based on changes in the underlying nature of the expenses.

Our evaluation of results of operations by each business segment includes an analysis of our SPP and our total property portfolio. SPP information allows us to evaluate the performance of our leased property portfolio under a consistent population by eliminating changes in the composition of our portfolio of properties. We identify our SPP as stabilized properties that remained in operations and were consistently reported as leased properties or RIDEA properties for the duration of the year-over-year comparison periods presented. Accordingly, it takes a stabilized property a minimum of 12 months in operations under a consistent reporting structure to be included in our SPP. Newly acquired operating assets are generally considered stabilized at the earlier of lease-up (typically when the tenant(s) controls the physical use of at least 80% of the space) or 12 months from the acquisition date. Newly completed developments, including redevelopments, are considered stabilized at the earlier of lease-up or 24 months from the date the property is placed in service. SPP NOI excludes certain non-property specific operating expenses that are allocated to each operating segment on a consolidated basis.

Comparison of the Three Months Ended March 31, 2013 to the Three Months Ended March 31, 2012

During the fourth quarter of 2012 and first quarter of 2013, we acquired a portfolio of 133 senior housing communities (the Blackstone JV Acquisition , see additional information in Note 3 to the Condensed Consolidated Financial Statements). The transaction closed in two stages: (i) 129 senior housing facilities during the fourth quarter of 2012 for \$1.7 billion; and (ii) four senior housing facilities during the first quarter of 2013 for \$38 million. The results of operations from the acquisitions are reflected in our condensed consolidated financial statements from those respective dates.

Segment NOI and Adjusted NOI

The tables below provide selected operating information for our SPP and total property portfolio for each of our five business segments. Our consolidated SPP consists of 924 properties representing properties acquired or placed in service and stabilized on or prior to January 1, 2012 and that remained in operations under a consistent reporting structure through March 31, 2013. Our consolidated total property portfolio represents 1,090 and 935 properties at March 31, 2013 and 2012, respectively, and excludes properties classified as discontinued operations.

Results are as of and for the three months ended March 31, 2013 and 2012 (dollars and square feet in thousands except per capacity data):

Senior Housing

	2013	SPP 2012	Change	2013	Tot	tal Portfolio 2012	Change
Rental revenues(1)	\$ 115,575	\$ 113,500	\$ 2,075	\$ 149,091	\$	113,500	\$ 35,591
Resident fees and services	36,891	36,179	712	36,891		36,179	712
Total revenues	152,466	149,679	2,787	185,982		149,679	36,303
Operating expenses	(23,498)	(20,966)	(2,532)	(24,391)		(21,614)	(2,777)
NOI	128,968	128,713	255	161,591		128,065	33,526
Straight-line rents	(6,118)	(7,910)	1,792	(13,177)		(7,910)	(5,267)
DFL accretion	(5,031)	(5,149)	118	(5,031)		(5,149)	118
	(358)	(358)		(190)		(358)	168

Edgar Filing: HCP, INC. - Form 10-Q

Amortization of above and

below market

lease intangibles, net						
Adjusted NOI	\$ 117,461	\$ 115,296	\$ 2,165 \$	143,193	\$ 114,648	\$ 28,545
Adjusted NOI % change			1.9%			
Property count(2)	312	312		445	312	
Average capacity (units)(3)	35,401	35,396		45,402	35,396	
Average annual rent per						
unit(4)	\$ 13,292	\$ 13,056	\$	12,710	\$ 13,056	

⁽¹⁾ Represents rental and related revenues and income from direct financing leases (DFLs).

⁽²⁾ From our past presentation of SPP for the three months ended March 31, 2012, we removed two senior housing properties from SPP that were sold or classified as held for sale.

Represents average capacity as reported by the respective tenants or operators for the twelve-month period and a quarter in arrears from the periods (3) presented.

Average annual rent per unit, includes operating income from properties under a RIDEA structure that are based on NOI. (4)

Table of Contents

SPP NOI and Adjusted NOI. SPP NOI increased primarily as a result of rent escalations related to new leases or leases not subject to straight-line rents. SPP adjusted NOI improved primarily as a result of annual rent escalations and an increase in rental revenues from properties that were previously transitioned from Sunrise to other operators. The increases in SPP NOI and adjusted NOI were partially offset by a decline in additional rents, which are based on the facility s performance.

Total Portfolio NOI and Adjusted NOI. Including the impact of our SPP, our total portfolio NOI and adjusted NOI primarily increased as a result of our Blackstone JV Acquisition.

Post-Acute/Skilled Nursing

		SPP				Tot	tal Portfolio	
	2013	2012	Change		2013		2012	Change
Rental revenues(1)	\$ 136,103	\$ 133,673	\$ 2,430	\$	136,103	\$	133,673	\$ 2,430
Operating expenses	(146)	(198)	52		(647)		(200)	(447)
NOI	135,957	133,475	2,482		135,456		133,473	1,983
Straight-line rents	(170)	(163)	(7)		(170)		(163)	(7)
DFL accretion	(19,139)	(20,473)	1,334		(19,139)		(20,473)	1,334
Amortization of								
above and below								
market lease								
intangibles, net	11	11			11		11	
Adjusted NOI	\$ 116,659	\$ 112,850	\$ 3,809	\$	116,158	\$	112,848	\$ 3,310
Adjusted NOI %								
change			3.4%	ó				
Property count(2)	312	312			312		312	
Average capacity								
(beds)(3)	39,855	39,798			39,855		39,798	
Average annual rent								
per bed	\$ 11,722	\$ 11,361		\$	11,722	\$	11,361	

⁽¹⁾ Represents rental and related revenues and income from DFLs.

NOI and Adjusted NOI. SPP and total portfolio NOI and adjusted NOI primarily increased as a result of annual rent escalations from 268 post-acute/skilled nursing facilities classified as DFLs from HCR ManorCare, Inc. (see Notes 5 and 11 to the Condensed Consolidated Financial Statements for additional information regarding the net investment in DFLs and HCR ManorCare, respectively).

⁽²⁾ From our past presentation of SPP for the three months ended March 31, 2012, we removed a post-acute/skilled nursing property from SPP that was sold or classified as held for sale.

⁽³⁾ Represents average capacity as reported by the respective tenants or operators for the twelve-month period and a quarter in arrears from the periods presented.

Life Science

	2013	SPP 2012		Change			2013	Total Portfolio 2012			Change	
Rental and related												
revenues	\$ 60,129	\$	59,887	\$	242	\$	62,438	\$	61,410	\$	1,028	
Tenant recoveries	10,505		10,279		226		10,892		10,420		472	
Total revenues	70,634		70,166		468		73,330		71,830		1,500	
Operating expenses	(11,794)		(11,687)		(107)		(13,383)		(12,884)		(499)	
NOI	58,840		58,479		361		59,947		58,946		1,001	
Straight-line rents	(3,331)		340		(3,671)		(3,692)		81		(3,773)	
Amortization of												
above and												
below market lease												
intangibles, net	97		89		8		85		77		8	
Adjusted NOI	\$ 55,606	\$	58,908	\$	(3,302)	\$	56,340	\$	59,104	\$	(2,764)	
Adjusted NOI %												
change					(5.6)%	, o						
Property count	101		101				110		108			
Average occupancy	92.7%		90.9%				91.4%		88.9%			
Average occupied												
square feet	6,195		6,079				6,423		6,146			
Average annual rent												
per occupied sq. ft.	\$ 44	\$	46			\$	43	\$	47			

NOI and Adjusted NOI. SPP and total portfolio NOI increased primarily as a result of an increase in life science occupancy, partially offset by mark-to-market rent reductions. SPP and total portfolio adjusted NOI decreased primarily as a result of a \$4 million rent payment received in February 2012 in connection with a lease amendment and mark-to-market rent reductions, partially offset by annual rent escalations and an increase in life science occupancy.

During the three months ended March 31, 2013, 183,000 square feet of new and renewal leases commenced at an average annual base rent of \$33.17 per square foot compared to 105,000 square feet of expiring with an average annual base rent of \$50.31 per square foot.

Medical Office

	2013	SPP 2012	(Change	2013	Tot	al Portfolio 2012	(Change
Rental and related revenues	\$ 66,438	\$ 66,125	\$	Ü	\$ 74,507	\$	68,297	\$	6,210
Tenant recoveries	11,231	11,545		(314)	12,748		11,658		1,090
Total revenues	77,669	77,670		(1)	87,255		79,955		7,300
Operating expenses	(29,446)	(29,358)		(88)	(34,296)		(31,705)		(2,591)
NOI	48,223	48,312		(89)	52,959		48,250		4,709
Straight-line rents	(1,048)	(1,315)		267	(1,522)		(1,359)		(163)
Amortization of above and below									
market lease intangibles, net	98	67		31	234		30		204
Adjusted NOI	\$ 47,273	\$ 47,064	\$	209	\$ 51,671	\$	46,921	\$	4,750
Adjusted NOI % change				0.4%					
Property count(1)	183	183			206		186		
Average occupancy	91.5%	91.1%			91.2%		91.1%		
Average occupied square feet	11,591	11,508			12,915		11,844		
Average annual rent per occupied									
sq. ft.	\$ 26	\$ 26			\$ 27	\$	26		

⁽¹⁾ From our past presentation of SPP for the three months ended March 31, 2012, we removed three MOBs that were placed into redevelopment in 2012 and 2013, which no longer meet our criteria for SPP as of the date they were placed into redevelopment.

SPP Portfolio NOI and Adjusted NOI. SPP adjusted NOI increased primarily as a result of rent escalations, partially offset by a one-time rental revenue adjustment.

Total Portfolio NOI and Adjusted NOI. In addition to the impact from our SPP, NOI and adjusted NOI increased primarily as a result of the impact of our MOB acquisitions during 2012.

During the quarter ended March 31, 2013, 340,000 square feet of new and renewal leases commenced at an average annual base rent of \$24.36 per square foot compared to 580,000 square feet of expiring and terminated leases with an average annual base rent of \$24.33 per square foot.

Hospital

	2013	SPP 2012	Change	2013	Tota	al Portfolio 2012	(Change
Rental and related revenues	\$ 19,068	\$ 18,042	\$ 1,026	\$ 20,207	\$	18,806	\$	1,401
Tenant recoveries	563	572	(9)	563		572		(9)
Total revenues	19,631	18,614	1,017	20,770		19,378		1,392
Operating expenses	(887)	(929)	42	(888)		(930)		42
NOI	18,744	17.685	1,059	19,882		18,448		1,434

Straight-line rents	(90)	(184)	94	(232)	(337)	105
Amortization of above and						
below market lease intangibles, net	(192)	(192)		(218)	(218)	
Adjusted NOI	\$ 18,462	\$ 17,309	\$ 1,153 \$	19,432	\$ 17,893	\$ 1,539
Adjusted NOI % change			6.7%			
Property count	16	16		17	17	
Average capacity (beds)(1)	2,379	2,375		2,410	2,406	
Average annual rent per bed	\$ 32,533	\$ 30,723	\$	33,726	\$ 31,300	

⁽¹⁾ Represents capacity as reported by the respective tenants or operators for the twelve-month period and a quarter in arrears from the periods presented. Certain operators in our hospital portfolio are not required under their respective leases to provide operational data.

NOI and Adjusted NOI. NOI and adjusted NOI increased primarily as a result of a new lease on our Plano hospital.

Other Income and Expense Items

Interest income

Interest income increased \$11.6 million to \$12.4 million for the three months ended March 31, 2013. The increase was primarily the result of interest income from our mezzanine loan facility to Tandem Health Care and our Four Seasons Health Care senior unsecured notes made in 2012 (see Notes 6 and 9, respectively, to the Condensed Consolidated Financial Statements for additional information).

Interest expense

Interest expense increased \$5.6 to \$109.4 million for the three months ended March 31, 2013. The increase was primarily from our senior unsecured notes offerings during 2012, net of related maturities of certain senior unsecured notes during 2012 and 2013.

Our exposure to expense fluctuations related to our variable rate indebtedness is substantially mitigated by our interest rate swap contracts. For a more detailed discussion of our interest rate risk, see

Quantitative and Qualitative Disclosures About Market Risk in Item 7A.

The table below sets forth information with respect to our debt, excluding premiums and discounts (dollars in thousands):

	As of Mar	ch 31,(1))
	2013		2012
Balance:			
Fixed rate	\$ 8,442,891	\$	7,607,626
Variable rate	54,365		48,835
Total	\$ 8,497,256	\$	7,656,461
Percent of total debt:			
Fixed rate	99%		99%
Variable rate	1		1
Total	100%		100%
Weighted average interest rate at end of period:			
Fixed rate	5.24%		5.72%
Variable rate	1.46%		1.44%
Total weighted average rate	5.22%		5.69%

⁽¹⁾ Excludes \$79 million and \$87 million at March 31, 2013 and 2012, respectively, of other debt that represents non-interest bearing life care bonds and occupancy fee deposits at certain of our senior housing facilities, which have no scheduled maturities. At March 31, 2013, \$86 million of variable-rate mortgages and £137 million (\$208 million) term loan are presented as fixed-rate debt as the interest payments under such debt have been swapped (pay fixed and receive float). At March 31, 2012, \$87 million of variable-rate mortgages are presented as fixed-rate debt as the interest payments under such debt have been swapped (pay fixed and receive float); the interest rates for swapped debt are presented at the swapped rates.

Depreciation and amortization expense
Depreciation and amortization expense increased \$19.4 million to \$104.7 million for the three months ended March 31, 2013. The increase was primarily the result of the impact of our Blackstone JV Acquisition.
General and administrative expenses
General and administrative expenses increased \$0.7 million to \$20.7 million for the three months ended March 31, 2013. The increase was primarily due to increases in compensation related expenses and acquisition pursuit costs, which increases were partially offset by a decrease in legal fees.
Other income, net
Other income, net increased \$11.6 million to \$12.0 million for the three months ended March 31, 2013. The increase was primarily the result of gains from the sale of marketable equity securities during 2013 of \$11 million.

Table	αf	Contents

Equity income from unconsolidated joint ventures

Equity income from unconsolidated joint ventures increased \$1.1 million to \$14.8 million for the three months ended March 31, 2013. The increase was primarily the result of an increase in our share of earnings from our interest in HCR ManorCare, Inc. (see Notes 7 and 11 to the Condensed Consolidated Financial Statements for additional information).

Liquidity and Capital Resources

Our principal liquidity needs are to: (i) fund recurring operating expenses, (ii) meet debt service requirements including principal payments and maturities in the last nine months of 2013, (iii) fund capital expenditures, including tenant improvements and leasing costs, (iv) fund acquisition and development activities, and (v) make dividend distributions. During the three months ended March 31, 2013, distributions to shareholders and noncontrolling interest holders exceeded cash flows from operations by approximately \$28 million that was primarily funded with available cash. We anticipate that cash flow from continuing operations over the next 12 months will be adequate to fund our business operations, debt service payments, recurring capital expenditures and cash dividends to shareholders. Capital requirements relating to maturing indebtedness, acquisitions and development activities may require funding from borrowings and/or equity and debt offerings.

Access to capital markets impacts our cost of capital and ability to refinance maturing indebtedness, as well as our ability to fund future acquisitions and development through the issuance of additional securities or secured debt. Credit ratings impact our ability to access capital and directly impact our cost of capital as well. For example, as noted below, our revolving line of credit facility accrues interest at a rate per annum equal to LIBOR plus a margin that depends upon our debt ratings. We also pay a facility fee on the entire revolving commitment that depends upon our debt ratings. As of April 25, 2013, we had a credit rating of BBB+ from Fitch, Baa1 from Moody s and BBB+ from S&P on our senior unsecured debt securities.

Net cash provided by operating activities was \$214 million and \$186 million for the three months ended March 31, 2013 and 2012, respectively. The increase in operating cash flows is primarily the result of the following: (i) the impact of our investments in 2012 and 2013, (ii) assets placed in service during 2012 and 2013 and (iii) rent escalations and resets in 2012 and 2013, which increases were partially offset by increased debt interest payments. Our cash flows from operations are dependent upon the occupancy level of multi-tenant buildings, rental rates on leases, our tenants performance on their lease obligations, the level of operating expenses and other factors.

The following are significant investing and financing activities for the three months ended March 31, 2013:

- made investments of \$88 million (development and acquisition of real estate and funding of loans);
- sold marketable equity securities for \$28 million;

 paid dividends on common stock of \$238 million, which were generally funded by cash provided by our operating activities; and
• repaid \$150 million of senior unsecured notes.
Debt
Bank Line of Credit and Term Loan
Our \$1.5 billion unsecured revolving line of credit facility (the Facility) matures on March 2016 and contains a one-year extension option. Borrowings under this Facility accrue interest at LIBOR plus a margin that depends upon our debt ratings. We pay a facility fee on the entire revolving commitment that depends on our debt ratings. Based on our debt ratings at April 25, 2013, the margin on the Facility was 1.075%, and the facility fee was 0.175%. The Facility also includes a feature that will allow us to increase the borrowing capacity by an aggregate amount of up to \$500 million, subject to securing additional commitments from existing lenders or new lending institutions. At March 31, 2013, we had \$14 million outstanding under the Facility.
On July 30, 2012, we entered into a credit agreement with a syndicate of banks for a £137 million (\$208 million at March 31, 2013) four-year unsecured Term Loan (the Term Loan) that accrues interest at a rate of GBP LIBOR plus 1.20%, based on our current debt ratings. Concurrent with the closing of the Term Loan, we entered into a four-year interest rate swap agreement that fixed the rate of the Term Loan at 1.81%, subject to adjustments based on our credit ratings. The Term Loan contains a one-year committed extension option.

Table of Contents

The Facility and Term Loan contain certain financial restrictions and other customary requirements. Among other things, these covenants, using terms defined in the agreements (i) limit the ratio of Consolidated Total Indebtedness to Consolidated Total Asset Value to 60%, (ii) limit the ratio of Secured Debt to Consolidated Total Asset Value to 30%, (iii) limit the ratio of Unsecured Debt to Consolidated Unencumbered Asset Value to 60%, (iv) require a minimum Fixed Charge Coverage ratio of 1.5 times and (v) require a formula-determined Minimum Consolidated Tangible Net Worth of \$9.2 billion at March 31, 2013. At March 31, 2013, we were in compliance with each of these restrictions and requirements of the Facility and Term Loan.

Our Facility also contains cross-default provisions to other indebtedness of ours, including in some instances, certain mortgages on our properties. Certain mortgages contain default provisions relating to defaults under the leases or operating agreements on the applicable properties by our operators or tenants, including default provisions relating to the bankruptcy filings of such operator or tenant. Although we believe that we would be able to secure amendments under the applicable agreements if a default as described above occurs, such a default may result in significantly less favorable borrowing terms than currently available, material delays in the availability of funding or other material adverse consequences.

Senior Unsecured Notes

At March 31, 2013, we had senior unsecured notes outstanding with an aggregate principal balance of \$6.6 billion. Interest rates on the notes ranged from 1.25% to 6.98% with a weighted average effective interest rate of 5.10% and a weighted average maturity of six years at March 31, 2013. The senior unsecured notes contain certain covenants including limitations on debt, maintenance of unencumbered assets, cross-acceleration provisions and other customary terms. We believe we were in compliance with these covenants at March 31, 2013.

Mortgage Debt

At March 31, 2013, we had \$1.7 billion in aggregate principal amount of mortgage debt outstanding that is secured by 139 healthcare facilities (including redevelopment properties) with a carrying value of \$2.1 billion. Interest rates on the mortgage debt ranged from 1.54% to 8.69% with a weighted average effective interest rate of 6.13% and a weighted average maturity of three years at March 31, 2013.

Mortgage debt generally requires monthly principal and interest payments, is collateralized by certain properties and is generally non-recourse. Mortgage debt typically restricts transfer of the encumbered properties, prohibits additional liens, restricts prepayment, requires payment of real estate taxes, requires maintenance of the assets in good condition, requires maintenance of insurance on the assets and includes conditions to obtain lender consent to enter into and terminate material leases. Some of the mortgage debt is also cross-collateralized by multiple properties and may require tenants or operators to maintain compliance with the applicable leases or operating agreements of such real estate assets.

Other Debt

At March 31, 2013, we had \$79 million of non-interest bearing life care bonds at two of our continuing care retirement communities and non-interest bearing occupancy fee deposits at two of our senior housing facilities, all of which were payable to certain residents of the facilities

(collectively, Life Care Bonds). The Life Care Bonds are refundable to the residents upon the termination of the contract or upon the successful resale of the unit.

Debt Maturities

The following table summarizes our stated debt maturities and scheduled principal repayments at March 31, 2013 (in thousands):

Year	Amount(1)
2013 (Nine months)	\$ 683,104
2014	667,221
2015	708,611
2016	1,414,154
2017	1,300,698
Thereafter	3,723,468
	8,497,256
(Discounts) and premiums, net	(30,502)
	\$ 8,466,754
(Discounts) and premiums, net	\$ (30,502)

⁽¹⁾ Excludes \$79 million of other debt that represents Life Care Bonds that have no scheduled maturities.

Table of Contents

Derivative Instruments

We use derivative instruments to mitigate the effects of interest rate and foreign exchange fluctuations on specific forecasted transactions as well as recognized financial obligations or assets. We do not use derivative instruments for speculative or trading purposes.

The following table summarizes our outstanding interest rate and foreign exchange swap contracts as of March 31, 2013 (dollars and GBP in thousands):

				Fixed					
		Hedge Rate/Buy Floating/Exchange Notional/							
Date Entered	Maturity Date	Designation		Amount	Rate Index	S	ell Amount		Fair Value
July 2005(1)	July 2020	Cash Flow		3.82%	BMA Swap Index	\$	45,600	\$	(8,189)
November 2008	October 2016	Cash Flow		5.95%	1 Month LIBOR+1.50%	\$	26,900	\$	(3,603)
July 2009	July 2013	Cash Flow		6.13%	1 Month LIBOR+3.65%	\$	13,600	\$	(79)
					1 Month GBP				
July 2012	June 2016	Cash Flow		1.81%	LIBOR+1.20%	£	137,000	\$	(549)
July 2012	June 2016	Cash Flow	\$	79,600	Buy USD/Sell GBP	£	50,700	\$	2,490

For a more detailed description of our derivative instruments, see Note 19 to the Condensed Consolidated Financial Statements and Item 3. *Quantitative and Qualitative Disclosures About Market Risk*.

Equity

At March 31, 2013, we had 454 million shares of common stock outstanding. At March 31, 2013, equity totaled \$10.8 billion, and our equity securities had a market value of \$23 billion.

At March 31, 2013, there were a total of four million DownREIT units outstanding in four limited liability companies in which we are the managing member. The DownREIT units are exchangeable for an amount of cash approximating the then-current market value of shares of our common stock or, at our option, shares of our common stock (subject to certain adjustments, such as stock splits and reclassifications).

Shelf Registration

We have a prospectus that we filed with the U.S. Securities and Exchange Commission (SEC) as part of a registration statement on Form S-3ASR, using a shelf registration process which expires in July 2015. Under the shelf process, we may sell any combination of the securities in one or more offerings. The securities described in the prospectus include common stock, preferred stock, depositary shares, debt securities and warrants.

The prospectus only provides a general description of the securities we may offer. The prospectus may not be used to sell securities unless accompanied by a prospectus supplement or a free writing prospectus. Each time we sell securities under the shelf registration, we will provide a prospectus supplement that will contain specific information about the terms of the securities being offered and of the offering. The prospectus supplement may also add, update or change information contained in the prospectus.

We may offer and sell the securities pursuant to the prospectus through underwriters, dealers or agents or directly to purchasers, on a continuous or delayed basis. The securities may also be resold by selling security holders. The prospectus supplement for each offering will describe in detail the plan of distribution for that offering and will set forth the names of any underwriters, dealers or agents involved in the offering and any applicable fees, commissions or discount arrangements. We intend to use the net proceeds from the sales of the securities as set forth in the applicable prospectus supplement, and unless otherwise set forth in a therein, we will not receive any proceeds if the securities are sold by a selling security holder.

Funds From Operations (FFO)

We believe FFO applicable to common shares, diluted FFO applicable to common shares, and basic and diluted FFO per common share are important supplemental non-GAAP measures of operating performance for a REIT. Because the historical cost accounting convention used for real estate assets utilizes straight-line depreciation (except on land), such accounting presentation implies that the value of real estate assets diminishes predictably over time. Since real estate values instead have historically risen and fallen with market conditions, presentations of operating results for a REIT that uses historical cost accounting for depreciation could be less informative. The term FFO was designed by the REIT industry to address this issue.

FFO is defined as net income applicable to common shares (computed in accordance with GAAP), excluding gains or losses from acquisition and dispositions of depreciable real estate or related interests, impairments of, or related to, depreciable real estate, plus real estate and DFL depreciation and amortization, with adjustments for joint ventures. Adjustments for joint ventures are calculated to reflect FFO on the same basis. FFO does not represent cash generated from operating activities in accordance with GAAP, is not necessarily indicative of cash available to fund cash needs and should not be considered an alternative to net income. We compute FFO in accordance with the current National Association of Real Estate Investment Trusts (NAREIT) definition; however, other REITs may report FFO differently or have a different interpretation of the current NAREIT definition from us. In addition, we present FFO before the impact of litigation settlement charges, preferred stock redemption charges, impairments (recoveries) of non-depreciable assets and merger-related items (defined below) (FFO as adjusted). Management believes FFO as adjusted is a useful alternative measurement. This measure is a modification of the NAREIT definition of FFO and should not be used as an alternative to net income (determined in accordance with GAAP).

Details of certain items that affect comparability are discussed under *Results of Operations* above. The following is a reconciliation of net income applicable to common shares, the most direct comparable financial measure calculated and presented in accordance with GAAP, to FFO and FFO as adjusted (in thousands, except per share data):

	Three Months En 2013	nded Ma	arch 31, 2012
Net income applicable to common shares	\$ 230,107	\$	175,257
Depreciation and amortization of real estate, in-place lease and other intangibles:			
Continuing operations	104,717		85,280
Discontinued operations			2,996
DFL depreciation	3,429		3,050
Gain on sales of real estate			(2,856)
Equity income from unconsolidated joint ventures	(14,801)		(13,675)
FFO from unconsolidated joint ventures	17,541		16,177
Noncontrolling interests and participating securities share in earnings	3,677		4,301
Noncontrolling interests and participating securities share in FFO	(5,141)		(5,724)
FFO applicable to common shares	339,529		264,806
Distributions on dilutive convertible units	3,328		3,122
Diluted FFO applicable to common shares	\$ 342,857	\$	267,928
Diluted FFO per common share	\$ 0.74	\$	0.64
Weighted average shares used to calculate diluted FFO per common share	460.650		417,524
weighted average shares used to calculate diluted 110 per common share	400,030		417,324
Impact of adjustments to FFO:			
Preferred stock redemption charge(1)	\$	\$	10,432
FFO as adjusted applicable to common shares	\$ 339,529	\$	275,238
Distributions on dilutive convertible units and other	3,328		3,089
Diluted FFO as adjusted applicable to common shares	\$ 342,857	\$	278,327
Diluted FFO as adjusted per common share	\$ 0.74	\$	0.67
Weighted average shares used to calculate diluted FFO as adjusted per			
common share	460,650		417,524

⁽¹⁾ In connection with the redemption of our preferred stock, during the three months ended March 31, 2012, we incurred a redemption charge of \$10.4 million related to the original issuance costs.

Off-Balance Sheet Arrangements

We own interests in certain unconsolidated joint ventures as described under Note 7 to the Condensed Consolidated Financial Statements. Except in limited circumstances, our risk of loss is limited to our investment in the joint venture and any outstanding loans receivable. In addition, we have certain properties which serve as collateral for debt that is owed by a previous owner of certain of our facilities, as described under Note 11 to the Condensed Consolidated Financial Statements. Our risk of loss for these certain properties is limited to the outstanding debt balance plus penalties, if any. We have no other material off-balance sheet arrangements that we expect would materially affect our liquidity and capital resources except those described below under *Contractual Obligations*.

33

Contractual Obligations

The following table summarizes our material contractual payment obligations and commitments at March 31, 2013 (in thousands):

	Total(1)	Less than One Year	2014-2015	2016-2017	More than Five Years
Line of credit	\$ 14,000	\$	\$	\$ 14,000	\$
Term loan(2)	208,213			208,213	
Senior unsecured notes	6,587,000	400,000	887,000	1,650,000	3,650,000
Mortgage debt	1,688,043	283,104	488,832	842,639	73,468
Construction loan commitments(3)	35,259	21,272	13,987		
Development commitments(4)	14,103	13,148	955		
Ground and other operating leases	228,723	5,891	13,720	10,162	198,950
Interest(5)	2,402,187	267,191	718,998	527,862	888,136
Total	\$ 11,177,528	\$ 990,606	\$ 2,123,492	\$ 3,252,876	\$ 4,810,554

⁽¹⁾ Excludes \$79 million of other debt that represents Life Care Bonds that have no scheduled maturities.

Inflation

Our leases often provide for either fixed increases in base rents or indexed escalators, based on the Consumer Price Index or other measures, and/or additional rent based on increases in the tenants—operating revenues. Most of our MOB leases require the tenant to pay a share of property operating costs such as real estate taxes, insurance and utilities. Substantially all of our senior housing, life science, post-acute/skilled nursing and hospital leases require the operator or tenant to pay all of the property operating costs or reimburse us for all such costs. We believe that inflationary increases in expenses will be offset, in part, by the operator or tenant expense reimbursements and contractual rent increases described above.

Recent Accounting Pronouncements

See Note 2 to the Condensed Consolidated Financial Statements for the impact of new accounting standards. There are no accounting pronouncements that have been issued, but not yet adopted by us, that we believe will materially impact our condensed consolidated financial statements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

⁽²⁾ Represents £137 million translated into U.S. dollars.

⁽³⁾ Represents commitments to finance development projects and related working capital financings.

⁽⁴⁾ Represents construction and other commitments for developments in progress.

⁽⁵⁾ Interest on variable-rate debt is calculated using rates in effect at March 31, 2013.

We use derivative financial instruments in the normal course of business to mitigate interest rate and foreign currency risk. We do not use derivative financial instruments for speculative or trading purposes. Derivatives are recorded on the condensed consolidated balance sheets at their fair value. See Note 19 to the Condensed Consolidated Financial Statements for additional information.

To illustrate the effect of movements in the interest rate and foreign currency markets, we performed a market sensitivity analysis on our hedging instruments. We applied various basis point spreads to the underlying interest rate curves and foreign currency exchange rates of the derivative portfolio in order to determine the instruments—change in fair value. Assuming a one percentage point change in the underlying interest rate curve and foreign currency exchange rates, the estimated change in fair value of each of the underlying derivative instruments would not exceed \$7 million. See Note 19 to the Condensed Consolidated Financial Statements for additional analysis details.

Interest Rate Risk. At March 31, 2013, we were exposed to market risks related to fluctuations in interest rates on properties with a gross value of \$83 million that are subject to leases where the payments fluctuate with changes in LIBOR (excludes \$208 million (£137 million) of variable-rate senior unsecured notes that have been hedged through interest-rate swap contracts). Our exposure to income fluctuations related to our variable-rate investments is partially offset by: (i) \$25 million of variable-rate senior unsecured notes; (ii) \$15 million of variable-rate mortgage debt payable (excludes \$86 million of variable-rate mortgage notes that have been hedged through interest-rate swap contracts); and (iii) \$14 million of variable-rate line of credit borrowings. Additionally, our exposure to market risks related to fluctuations in interest rates excludes our GBP denominated \$208 million (£137 million) variable-rate Term Loan that has been hedged through interest-rate swap contracts.

Table of Contents

Interest rate fluctuations will generally not affect our future earnings or cash flows on our fixed rate debt and assets unless such instruments mature or are otherwise terminated. However, interest rate changes will affect the fair value of our fixed rate instruments. Conversely, changes in interest rates on variable rate debt and investments would change our future earnings and cash flows, but not significantly affect the fair value of those instruments. Assuming a one percentage point increase in the interest rate related to the variable-rate investments and variable-rate debt, and assuming no other changes in the outstanding balance as of March 31, 2013, our annual interest expense would increase by approximately \$0.3 million, or less than \$0.01 per common share on a diluted basis.

Foreign Currency Risk. At March 31, 2013, our exposure to foreign currency exchange rates relates to forecasted interest receipts from our GBP denominated senior unsecured notes (see additional discussion of the Four Seasons Health Care Senior Unsecured Notes in Note 9 to the Condensed Consolidated Financial Statements). Our foreign currency exchange exposure is mitigated by the forecasted interest and principal payments from our GBP denominated unsecured Term Loan (see Note 10 to the Condensed Consolidated Financial Statements for additional information) and a foreign currency swap contract for approximately 85% of the forecasted interest receipts from our senior unsecured notes through the non-call period which ends on June 15, 2016.

Market Risk. We have investments in marketable debt securities classified as held-to-maturity, because we have the positive intent and ability to hold the securities to maturity. Held-to-maturity securities are recorded at amortized cost and adjusted for the amortization of premiums and discounts through maturity. We consider a variety of factors in evaluating an other-than-temporary decline in value, such as: the length of time and the extent to which the market value has been less than our current adjusted carrying value; the issuer s financial condition, capital strength and near-term prospects; any recent events specific to that issuer and economic conditions of its industry; and our investment horizon in relationship to an anticipated near-term recovery in the market value, if any. At March 31, 2013, the fair value and adjusted carrying value of marketable debt securities were \$226 million and \$208 million, respectively.

Item 4. Controls and Procedures

Disclosure Controls and Procedures. We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SEC s rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial Officer), to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Also, we have investments in certain unconsolidated entities. Our disclosure controls and procedures with respect to such entities are substantially more limited than those we maintain with respect to our consolidated subsidiaries.

As required by Rules 13a-15(b) and 15d-15(b) of the Securities Exchange Act of 1934, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial Officer), of the effectiveness of the design and operation of our disclosure controls and procedures as of March 31, 2013. Based upon that evaluation, our Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial Officer) concluded that our disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control Over Financial Reporting. There were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934) during the fiscal quarter to which this report relates that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

m	. 1		c	\sim			
Tal	hl	e	Ωt	\mathbf{C}	าท	te	nts

PART II. OTHER INFORMATION

Itam	1 1	Rick	Factors
Hem	IA.	KISK	FACIOIS

There are no material changes to the risk factors previously disclosed in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2012.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

(a)

None.

(b)

None.

(c)

The table below sets forth information with respect to purchases of our common stock made by us or on our behalf or by any affiliated purchaser, as such term is defined in Rule 10b-18(a)(3) of the Securities Exchange Act of 1934, as amended, during the three months ended March 31, 2013.

Period Covered	Total Number Of Shares Purchased(1)	Average Price Paid Per Share	Total Number Of Shares (Or Units) Purchased As Part Of Publicly Announced Plans Or Programs	Maximum Number (Or Approximate Dollar Value) Of Shares (Or Units) That May Yet Be Purchased Under The Plans Or Programs
January 1-31, 2013	14,630	\$ 47.07		- The state of the
February 1-28, 2013	23	46.51		
Total	14,653	47.07		

Item 6. Exhibits

- 2.2 Purchase and Sale Agreement, dated as of October 16, 2012, by and among BRE/SW Portfolio LLC, those owner entities listed on Schedule 1 thereto Corporation; and First Amendment to such Purchase and Sale Agreement, by and among such parties, dated as of December 4, 2012.**
- 3.1 Articles of Restatement of HCP (incorporated by reference to Exhibit 3.1 to HCP s Registration Statement on Form S-3 (Registration No. 333-18282)
- 10.1 Amendment No. 1, dated as of April 5, 2013, to the Employment Agreement, dated as of January 26, 2012, by and between the Company and Paul F. herein by reference to Exhibit 10.1 to HCP s Current Report on Form 8-K (File No. 1-08895) filed April 5, 2013).
- 10.2 Amendment No. 1, dated as of April 5, 2013, to the Employment Agreement, dated as of January 26, 2012, by and between the Company and Timoth (incorporated herein by reference to Exhibit 10.2 to HCP s Current Report on Form 8-K (File No. 1-08895) filed April 5, 2013).
- 10.3 Amendment No. 1, dated as of April 5, 2013, to the Employment Agreement, dated October 25, 2012, by and between the Company and James W. M. herein by reference to Exhibit 10.3 to HCP s Current Report on Form 8-K (File No. 1-08895) filed April 5, 2013).
- 10.4 Seventh Amendment to Master Lease and Security Agreement, dated as of February 11, 2013, by and among the parties signatory thereto and HCR II
- 31.1 Certification by James F. Flaherty III, HCP s Principal Executive Officer, Pursuant to Securities Exchange Act Rule 13a-14(a). *

⁽¹⁾ Represents restricted shares withheld under our 2006 Performance Incentive Plan (the 2006 Incentive Plan), to offset tax withholding obligations that occur upon vesting of restricted shares. Our 2006 Incentive Plan provides that the value of the shares withheld shall be the closing price of our common stock on the date the relevant transaction occurs.

Table of Contents

31.2	Certification by Timothy M. Schoen, HCP s Principal Financial Officer, Pursuant to Securities Exchange Act Rule 13a-14(a). *
32.1	Certification by James F. Flaherty III, HCP s Principal Executive Officer, Pursuant to Securities Exchange Act Rule 13a-14(b) and 18 U.S.C. Section 1350. **
32.2	Certification by Timothy M. Schoen, HCP s Principal Financial Officer, Pursuant to Securities Exchange Act Rule 13a-14(b) and 18 U.S.C. Section 1350. **
101.INS	XBRL Instance Document.*
101.SCH	XBRL Taxonomy Extension Schema Document.*
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document.*
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document.*
101.LAB	XBRL Taxonomy Extension Labels Linkbase Document.*
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document.*

^{*} Filed herewith.

Management Contract or Compensatory Plan or Arrangement.

^{**} Furnished herewith.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: May 2, 2013 HCP, Inc.

(Registrant)

/s/ JAMES F. FLAHERTY III

James F. Flaherty III

Chairman and Chief Executive Officer
(Principal Executive Officer)

/s/ TIMOTHY M. SCHOEN Timothy M. Schoen Executive Vice President-Chief Financial Officer (Principal Financial Officer)

/s/ SCOTT A. ANDERSON Scott A. Anderson Senior Vice President-Chief Accounting Officer (Principal Accounting Officer)

38